Category: Health

Federal health regulators announced Wednesday they have given the green light to a new treatment for a rare inherited disease developed by Denali Therapeutics.

This regulatory approval represents a milestone achievement for the pharmaceutical company, marking their inaugural FDA clearance in the United States.

Following the announcement, Denali’s stock price climbed 4.2% to reach $21.86 per share.

The newly approved medication, which will be sold under the brand name Avlayah, serves as an enzyme replacement treatment designed to combat Hunter syndrome. This uncommon inherited condition causes harmful accumulation of specific sugar compounds throughout the brain and other organs.

Hunter syndrome develops when patients lack sufficient amounts of the enzyme iduronate-2-sulfatase, leaving their bodies unable to properly process large sugar molecules known as glycosaminoglycans.

Federal health officials project that more than half of Americans over 65 will require assistance with basic daily tasks like bathing, dressing, or eating at some point in their lives, with some studies indicating this figure could reach two-thirds.

Despite this likelihood, very few older Americans carry private long-term care insurance. According to AHIP, a health insurance industry trade group, just 3% to 4% of Americans over 50 maintain active extended care policies. Medicare, the primary health coverage for seniors, typically doesn’t cover ongoing nursing home or assisted living services.

With the youngest baby boomers nearing their mid-60s, many families are counting on personal savings, family caregiving, or Medicaid, the joint federal-state program for low-income individuals. However, the first two approaches often fall short, while Medicaid qualification for residential care remains challenging due to strict income and asset requirements.

Long-term care specialists suggest considering a deliberate approach, particularly for middle-class families with moderate resources: systematically reducing assets to achieve Medicaid eligibility for nursing home or assisted living coverage more quickly.

This approach is called a Medicaid ‘spend down’ strategy.

To achieve Medicaid qualification for nursing home coverage, families must systematically and openly utilize a family member’s resources for legitimate expenses. Examples include using remaining assets to prepay funeral costs or purchase burial arrangements.

While intentionally lowering income and savings for Medicaid qualification may seem overwhelming, the alternative of unplanned long-term care expenses can rapidly deplete savings regardless. Assisted living and nursing home expenses often reach thousands monthly, typically forcing families to exhaust resources before receiving assistance.

Genworth Financial’s 2024 research revealed that home health aides average approximately $78,000 annually, while semi-private nursing home rooms cost roughly $111,000. This contrasts sharply with the median retirement savings of $200,000 for Americans aged 65 to 74, according to Federal Reserve data. An unexpected extended nursing home stay would consume these savings within two years.

‘There’s a reasonably high likelihood that you’ll need nursing care for a period of their lives, and there’s a good chance you may need it for a long period of time,’ said Eric Carlson, director of long-term services and supports advocacy with Justice in Aging, a national nonprofit legal advocacy organization focused on older Americans. Carlson has worked on these issues for 35 years.

Medicaid qualification for long-term or skilled nursing care typically requires low incomes and minimal assets, with specific limits varying by state. Most states require monthly income below $2,800 to $3,000. Individual asset limits generally cap at $2,000, excluding certain property like primary residences, vehicles, and personal belongings.

Given Medicaid eligibility’s complexity, eldercare professionals strongly recommend working with specialized advisors to ensure proper asset utilization and avoid accidentally disqualifying assistance applicants from Medicaid access.

For instance, families should avoid simply transferring assets from the care recipient’s accounts to family accounts to appear financially eligible. Medicaid applications typically include a five-year ‘look back’ review, where officials examine assets and accounts for improper transfers. It’s crucial to document expenses related to senior care costs, including out-of-pocket nursing home payments, medical bills, and personal necessities. Applicants may also use remaining assets for mortgage payments or debt reduction.

‘People shouldn’t be doing ‘do it yourself’ financial planning in these matters. It can create significant problems with a person’s estate,’ Carlson said. ‘You don’t want to wait until the day nursing care is absolutely necessary to make these sorts of decisions.’

Since Medicaid operates as a joint state-federal program, states manage these programs differently. New York residents whose income exceeds Medicaid limits can still qualify through an ‘excess income’ or spend-down program, deducting medical costs like doctor visits, prescriptions, or home care from income until meeting eligibility requirements. Once reaching that threshold, Medicaid covers additional care for the remaining month.

Similar ‘medically needy’ programs operate in over 30 states, enabling people with substantial healthcare expenses to qualify despite initially excessive income.

Carlson suggests utilizing resources like Justice for Aging, the Kaiser Family Foundation, and other eldercare advocates in local communities to navigate these challenges. Cities and states also provide Medicaid liaisons to guide families through the application process.

For those still years away from requiring nursing care, establishing long-term care plans remains essential, especially since most Americans will likely need such services eventually. One option involves purchasing long-term care insurance, typically acquired by individuals or families in their late 40s or early 50s. Monthly policies costing a few hundred dollars could eventually cover care expenses reaching tens of thousands annually.

German lawmakers are set to vote Friday on legislation that would impose taxes on sugar-laden beverages and prohibit the sale of energy drinks to anyone under 16 years old, as officials seek stronger measures to address rising obesity rates and associated health problems.

The Bundesrat, Germany’s assembly of regional states, will consider the proposal that would launch the formal legislative process for these health-focused restrictions. While the measure doesn’t outline specific tax structures, it suggests using generated revenue to fund public health programs.

Daniel Guenther, who leads Schleswig-Holstein and spearheaded the initiative, explained the rationale behind the proposed levy. “Manufacturers should have an incentive to revise their recipes and reduce sugar content. So far they have had no such incentive,” Guenther stated.

The legislation also targets energy drinks specifically due to their concentrated levels of caffeine, taurine and sugar. “Energy drinks are not harmless, trendy beverages,” Guenther emphasized. “They can become a real burden, especially for young people.”

According to World Health Organization data, over 100 nations currently impose taxes on sugar-sweetened beverages, including approximately half of European Union member countries like Belgium, France and Portugal. However, the EU lacks a unified policy, leaving individual governments to implement their own approaches.

Political support for the measure has grown beyond party lines, despite initial resistance from Guenther’s own conservative CDU party in February. Green Party representative Johannes Wagner endorsed the plan, arguing that beverage companies lack motivation to voluntarily reduce sugar content. “Anyone making profits from heavily sugared drinks must also contribute more to financing the resulting costs,” Wagner said.

Social Democrat Sabine Dittmar described the proposed tax as “sensible, necessary and long overdue,” advocating for a tiered system where beverages with higher sugar concentrations face steeper taxes than lower-sugar options.

Public opinion appears to favor stricter measures, with a February Forsa poll showing approximately 60% of Germans supporting taxes on high-sugar soft drinks.

Research from the Technical University of Munich in 2023 projected significant health and economic benefits from implementing a sugar tax similar to Britain’s model. The study estimated such a policy could decrease daily sugar consumption by 2-3 grams per person, prevent or postpone up to 244,000 type 2 diabetes cases over two decades, and generate savings of up to 16 billion euros ($17.3 billion) during that timeframe.

Industry representatives have pushed back against the proposal. Germany’s sugar industry association WVZ argues that imposing what they call a “punitive tax on sugar” might simply encourage manufacturers to substitute artificial sweeteners without delivering real health improvements.

WVZ Director General Guenter Tissen challenged the scientific basis for the policy. “A sugar tax creates the false impression that a single ingredient is to blame for the development of obesity. There is no scientifically reliable evidence for this,” Tissen said.

Federal health officials are reporting a substantial decrease in deaths among pregnant women nationwide, with maternal mortality rates falling by almost 20% since 2022, according to new data from the Centers for Disease Control and Prevention.

The decline follows the Supreme Court’s decision to overturn Roe v. Wade in 2022, which returned abortion regulation authority to individual states. According to a LifeNews.com analysis, “The improvement flatly contradicts repeated warnings from abortion advocates that protective pro-life laws would trigger a maternal health crisis by forcing women to carry high-risk pregnancies to term.”

The CDC data also indicates improvements in additional public health indicators during the same timeframe, suggesting broader positive trends in maternal care outcomes across the country.

Federal health regulators issued a warning Tuesday to biotech billionaire Dr. Patrick Soon-Shiong after he made misleading public statements about his company’s cancer treatment capabilities.

The Food and Drug Administration’s warning letter targets statements Soon-Shiong made on a podcast where he claimed his company’s bladder cancer medication could potentially treat, cure, or prevent various other cancer types.

The regulatory action focuses on promotional content for Anktiva, the primary product from ImmunityBio Inc., one of multiple biotech companies owned by Soon-Shiong, who also controls the Los Angeles Times newspaper.

Following the FDA’s public warning, ImmunityBio’s stock price dropped more than 24% during Tuesday’s trading session.

Federal approval for Anktiva came in 2024, specifically for treating a challenging form of bladder cancer. ImmunityBio continues seeking regulatory approval to use the medication for additional conditions, including certain lung and pancreatic cancers.

The problematic remarks occurred during a January broadcast of The Sean Spicer Show podcast, which carried the title “Is the FDA blocking life-saving cancer treatments?”

During the interview, Soon-Shiong called his company’s medication “the most important molecule that could cure cancer.” The executive chairman and chief medical officer later stated that although regulatory approval covers bladder cancer, “it actually can treat all cancers.”

He also claimed during the episode: “We have the therapy to prevent cancer if you were exposed to radiation, and that’s Anktiva.”

FDA officials determined these statements breach federal drug marketing regulations by generating “a misleading impression” about the medication’s capabilities.

Regulators additionally noted the podcast failed to include required information about potential risks and adverse effects, which may include urinary tract infections, pain, chills and fever. Federal law mandates that drug promotional materials present balanced information about both benefits and risks.

The FDA warning, directed to ImmunityBio CEO Richard Adcock, raises comparable issues with a television commercial for Anktiva. Both the advertisement and podcast incorrectly label the company’s treatment as a “cancer vaccine,” according to regulators.

The agency has given the company 15 days to address these violations and provide written plans for correction. By Tuesday afternoon, the podcast link had been taken down from ImmunityBio’s website.

Sarah Singleton, a spokesperson for the Culver City, California-based company, stated in an email that ImmunityBio considers the FDA’s warning “very seriously” and intends to “work cooperatively with the agency to address the matters raised in the letter.”

The Trump administration’s FDA has increased enforcement actions against pharmaceutical companies and online pharmacies, including oversight of executive appearances on television programs and podcasts.

European health authorities announced Tuesday that a critical shortage of cancer medications manufactured by Baxter International will likely continue through the first quarter of 2025.

The affected drugs contain ifosfamide, a chemotherapy agent used alone or combined with other treatments for testicular cancer, small cell cancer, and cervical cancer. Baxter serves as the main supplier of this medication throughout the European Union.

According to the European Medicines Agency, the supply disruption stems from technical problems at one of Baxter’s contract manufacturing facilities, though specific details about the issue were not revealed.

Three brand-name medications are impacted by the shortage: Holoxan, Tronoxal, and Mitoxana. These products either contain ifosfamide as their primary active ingredient or include it in combination with other cancer-fighting drugs.

Production of ifosfamide-based treatments stopped completely in September, but manufacturing has since restarted at reduced capacity levels.

This marks the second cancer drug shortage from Baxter in recent months. European regulators previously warned in February about limited supplies of cyclophosphamide, another chemotherapy drug found in Endoxan, Sendoxan, and Genoxal, also expected to last until early 2025 due to manufacturing site problems.

The medication shortages occur as ongoing Middle East conflicts threaten global medicine distribution through disrupted air travel and blocked shipping lanes.

Baxter International has not yet responded to requests for comment about the supply issues.

Massachusetts has experienced a dramatic increase in abortion services, with state officials documenting close to 50,000 procedures completed in or facilitated by the state during 2024. This figure represents more than twice the approximately 24,000 procedures recorded in 2023.

The significant jump stems largely from Massachusetts clinics expanding their reach beyond state borders. Roughly 25,000 of the total procedures involved abortion medications shipped to patients residing in states with restrictive abortion policies.

This interstate provision of abortion services has sparked legal challenges, with multiple state attorneys general initiating court cases against out-of-state medical providers who distribute abortion medications in violation of their local regulations.

India’s health ministry announced Tuesday that drug regulators have strengthened oversight of unauthorized weight-loss medication sales and marketing following the recent introduction of lower-cost generic alternatives to Ozempic and Wegovy over the weekend.

Six or more Indian pharmaceutical companies, including major players Dr Reddy’s, Zydus and Sun Pharma, introduced various branded versions of the popular diabetes and weight-loss medications, offering prices as much as 70% below Novo Nordisk’s original products in certain instances. This followed the expiration of semaglutide’s patent protection last week.

Semaglutide serves as the primary active ingredient in both Ozempic and Wegovy medications.

The patent’s expiration raised alarm about potential abuse and physician confusion as medication costs dropped dramatically.

According to the ministry’s announcement, the Central Drugs Standard Control Organization (CDSCO) performed inspections at 49 locations nationwide, encompassing pharmaceutical distributors, retail pharmacies, and weight-loss clinics.

The regulatory focus centered on detecting infractions involving unauthorized sales activities, inappropriate prescribing methods, and deceptive advertising practices, with violation notices issued to non-compliant organizations, the announcement stated.

“These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks,” the statement said, noting concerns about their widespread availability through multiple distribution channels.

The CDSCO issued warnings to pharmaceutical manufacturers earlier this month against direct or indirect promotional activities for weight-loss treatments, including obesity education programs that might function as disguised marketing efforts.

Industry experts anticipated over 40 Indian drug manufacturers would introduce more than 50 branded versions following patent expiration, competing for market share in a sector projected to expand to 80 billion rupees ($852.62 million) by 2030 from approximately 15 billion rupees currently, based on Pharmarack research firm data.

A growing number of Americans are embracing weight loss medications, with both injectable and oral forms gaining widespread acceptance as tools for shedding pounds and improving overall wellness.

Recent survey data from health research organization KFF reveals that approximately one in eight adults across the United States are currently using GLP-1 medications.

The popularity surge is evident in prescription numbers, with Novo Nordisk reporting over 600,000 prescriptions filled for their new oral Wegovy formulation since the beginning of January alone. Health data firm Truveta’s preliminary analysis indicates that more than one-third of these users are first-time patients trying these medications.

However, medical professionals stress that simply taking medication won’t deliver optimal results without accompanying changes to daily routines, including nutritious eating patterns, regular physical activity, sufficient rest, and effective stress reduction techniques.

“The biggest mistake people make with GLP-1 medications is thinking the prescription is the treatment,” explained Dr. Katherine Saunders, who specializes in obesity medicine at Weill Cornell Medicine and serves as co-founder of weight-loss treatment company FlyteHealth.

Research analyzing nearly three dozen studies demonstrates that while GLP-1 medications can produce weight reduction and health improvements independently, the results are more substantial and enduring when patients also implement lifestyle modifications.

Medical experts want patients to understand several key points about combining GLP-1 drugs with healthy behaviors:

While obesity contributes significantly to chronic health conditions like cardiovascular disease and diabetes, Dr. Jody Dushay, who practices endocrinology and obesity medicine at Harvard Medical School, emphasizes that overall wellness should take priority over scale readings alone.

“Health is what you eat, how much you move your body, what is your blood sugar, what is your blood pressure, what is your cholesterol,” Dushay explained. “All of those things are really important.”

These medications function by influencing hormones throughout the digestive system and brain, which reduces digestion speed while affecting hunger signals and satiety sensations. This mechanism “levels the playing field,” according to Saunders, creating better conditions for establishing healthier behaviors like portion control and increased physical activity.

“Social media and advertising sometimes create the impression that these medications are a quick fix, but obesity is a complex, chronic, progressive disease” requiring continuous medical oversight, Saunders noted.

Research studies testing weight loss drugs such as Wegovy and Zepbound incorporated organized lifestyle intervention programs alongside medication administration, with these comprehensive approaches recommended for every new patient.

This combined strategy produces not only meaningful weight reduction but also enhanced health indicators.

A study published in February examining more than 98,000 military veterans in the United States discovered that participants who used GLP-1 drugs while maintaining six to eight healthy lifestyle practices experienced a 43% reduction in risk for major cardiovascular incidents like strokes and heart attacks compared to those who avoided the medications and followed three or fewer healthy behaviors.

These lifestyle practices “can substantially amplify the benefits of modern medications,” observed Dr. Frank Hu, the study’s primary author and department chair for nutrition at Harvard T.H. Chan School of Public Health.

To optimize GLP-1 benefits while minimizing adverse effects such as nausea, vomiting, constipation, and muscle deterioration, Dushay and fellow specialists provide targeted recommendations.

Preserve muscle mass by consuming 20 to 30 grams of protein with each meal through sources like fish, poultry, yogurt, and legumes. Increase fiber consumption and water intake to 8-12 cups daily. For patients experiencing heartburn or nausea, eliminate fried and spicy foods from meals and avoid lying down immediately after eating.

Target 150 minutes of cardiovascular exercise weekly, or optimally around one hour daily. Include 30 minutes of resistance training two to three times per week through activities like weightlifting or resistance band exercises.

Prioritize adequate rest with seven to nine hours of sleep nightly for healthy adults. Implement strategies to minimize psychological and emotional stress.

Most importantly, maintain regular communication with healthcare providers regarding treatment progress. Medical experts point out that GLP-1 drugs can cause uncommon but severe adverse reactions.

“Someone really does need to keeping track of: What is the pace of your weight loss? What are your side effects? And not just mailing you a prescription every month,” Dushay emphasized.

Pharmaceutical giants Pfizer and French company Valneva announced Monday that their experimental Lyme disease vaccine demonstrated over 70% effectiveness in advanced clinical trials.

The American drugmaker revealed plans to pursue U.S. regulatory approval for the vaccine, designated PF-07307405.

Currently, no approved vaccine exists to protect against Lyme disease, which spreads through bites from infected blacklegged ticks. The last available vaccine, GSK’s Lymerix, was pulled from the market in 2002 due to low consumer interest.

The Pfizer-Valneva vaccine demonstrated 73.2% effectiveness beginning 28 days following the fourth dose. Initially, the trial fell short of its primary objective because fewer Lyme disease cases occurred than researchers expected, creating limited data for analysis.

A subsequent planned analysis achieved the target threshold, showing 74.8% effectiveness. This result boosted Pfizer’s confidence “in the vaccine’s potential” as the company prepares “submissions to regulatory authorities.”

The U.S. Centers for Disease Control and Prevention reports that Lyme disease symptoms include fever, headache, exhaustion, and a distinctive skin rash known as erythema migrans. Without treatment, the infection can affect joints, heart function, and the nervous system.

Healthcare providers can successfully treat most Lyme disease cases using several weeks of antibiotic therapy.

The CDC calculates that approximately 476,000 Americans receive Lyme disease diagnosis and treatment annually, while about 132,000 cases occur yearly across Europe, according to the pharmaceutical companies.

Valneva previously indicated it anticipates Pfizer will bring the vaccine to market during the latter half of 2027 following regulatory approval.

Two reproductive health facilities operated by Planned Parenthood in Indianapolis are set to permanently cease operations on April 3rd, according to the organization. Both clinics are situated within the Indianapolis metropolitan area.

The organization points to federal policies enacted under the Trump administration that limited taxpayer funding for abortion services as the primary factor behind these facility closures. Planned Parenthood, which operates as the country’s largest provider of abortion services, says these funding restrictions have made it financially unsustainable to maintain operations at these locations.

Separately, Indiana’s statewide prohibition on abortion procedures remains stalled in legal proceedings. A coalition of legal challengers argues that abortion access is integral to their religious beliefs and should therefore receive constitutional protection under First Amendment religious freedom provisions.

Multiple Indian pharmaceutical companies have introduced budget-friendly alternatives to the popular diabetes and weight-loss medications Ozempic and Wegovy, following the expiration of key patent protections in India last week.

The patent covering semaglutide, the primary component in Novo Nordisk’s blockbuster medications, lapsed in India, opening the door for domestic manufacturers to introduce their own versions at significantly reduced prices—approximately 70% less than the original drugs.

Industry experts anticipate that more than 40 Indian pharmaceutical companies will introduce over 50 alternative versions of the medication as they compete for market share in the global obesity treatment sector, which analysts project will reach $100 billion in value by 2030.

These manufacturers are also planning international expansion into markets including Canada, Brazil, other Latin American countries, and Turkey.

Sun Pharmaceutical, India’s top revenue-generating drug company, introduced two semaglutide products: Noveltreat for weight management and Sematrinity for diabetes treatment. Noveltreat carries a weekly price range of 900 to 2,000 rupees ($9.58-$21.30), while Sematrinity costs between 750 and 1,300 rupees ($7.99-$13.84) weekly.

Dr Reddy’s Laboratories from Hyderabad released Obeda for diabetes management in disposable pen format, with monthly costs around 4,200 rupees ($44.73) for either dosage strength.

Zydus Lifesciences introduced three branded versions—Semaglyn, Mashema, and Alterme—using reusable pen devices, with average monthly treatment costs of approximately 2,200 rupees ($23.43).

Torrent Pharmaceuticals developed both oral and injectable formulations under the names Sembolic and Semalix, with injectable versions starting at 3,999 rupees ($42.59) monthly.

Glenmark Pharmaceuticals launched GLIPIQ in both vial and pen formats for diabetes, with vial costs ranging from 1,300 to 1,760 rupees ($13.84-$18.74) for monthly use.

Alkem Laboratories created three branded products—Semasize, Obesema, and Hepaglide—in pre-filled disposable pens, with pricing beginning at 1,800 rupees ($19.17) per month.

Eris Lifesciences introduced Sundae in vial format, priced starting at 1,290 rupees ($13.74) monthly. The company has partnered with Natco Pharma for commercial production of the medication.

RALEIGH, N.C. — Claire Jefferies sought a two-hour escape from overwhelming headlines about international conflicts and economic pressures, finding solace through an increasingly popular wellness activity called forest bathing.

“When I’m here, it’s almost like a protective bubble around me,” the human resources director explained while standing among oak trees and blooming magnolias at Raleigh’s J.C. Raulston Arboretum. “It provides a shield.”

During the Sunday morning gathering, certified forest therapy guide Shawn Ramsey used a small brass bell to bring together approximately twelve participants for guided meditation, breathing techniques, and natural connection activities.

“I invite you to really spend the next 10 minutes just exploring this area,” Ramsey instructed with her eyes closed. “Really focusing on your breath, on your footsteps. All the natural sounds around you. Maybe the manmade sounds, too. Thinking about the forest’s natural rhythm and how are part of that here in this urban, forested environment.”

This wellness approach draws from Shinrin-yoku, a Japanese practice that research shows can decrease stress levels, enhance mood, reduce blood pressure, and strengthen immune system function.

Despite the arboretum’s location within a bustling metropolitan area, Ramsey emphasized that disconnecting from daily pressures and reconnecting with natural environments offers identical therapeutic benefits. She guided participants through different garden areas, encouraging them to crush evergreen branches between their hands to experience the scent, or simply make physical contact with tree bark.

“You know, in this day and age, there’s a lot of stress and anxiety and chaos,” she observed. “And people are searching for ways to kind of cope with that.”

Transportation safety researcher Alan Mintz attended with a companion and needed gentle reminders to avoid discussing current events during the session.

“I think it’s important for people to take the opportunity to exist in natural spaces, both to unwind and relax, so that it can be easier to interact with other people,” Mintz reflected while standing beneath filtered sunlight streaming through the tree canopy. “And to take a moment to appreciate beautiful things. That way, hopefully, they can carry that forward and have more of an appreciation for other people and other cultures that they might be less experienced with.”

Jefferies also had to gently redirect a friend who began discussing news topics while walking under the swaying branches overhead.

“That focus back into spending time in nature and the healing power of that, and just remembering that we’re part of something bigger, that we’re all connected,” said the mother of a 9-year-old son. “And that what we do in our actions that we take really matter to the rest of the world. And so there’s no better place to see that than here, where you can see all of the interconnectedness and the ways that this plant life naturally supports one another. Doesn’t take more than they need.”

Seasonal allergies bring misery to millions of Americans each year as pollen from trees, grasses and weeds triggers uncomfortable symptoms including runny noses, watery eyes, persistent coughing and frequent sneezing.

The severity of allergic reactions depends on several factors including geographic location, specific allergens that affect you, and daily habits. Medical professionals note that climate change has extended allergy seasons and increased their intensity, though they also emphasize that treatment options have improved significantly in recent years.

Medical experts offer practical advice for managing allergy symptoms that may even allow sufferers to spend time outdoors comfortably.

Each year, the Asthma and Allergy Foundation of America creates a list ranking the most difficult cities for allergy sufferers. Their assessment considers over-the-counter medication usage, pollen levels, and availability of allergy specialists.

The 2024 rankings place these five cities at the top: Boise, Idaho; San Diego; Tulsa, Oklahoma; Provo, Utah; and Rochester, New York.

Pollen consists of fine particles released by plants and trees during reproduction. Tree pollen dominates early spring, followed by grass pollination, then weed pollen in late summer and early autumn.

According to the Asthma and Allergy Foundation of America, problematic tree pollens include birch, cedar, cottonwood, maple, elm, oak and walnut varieties. Troublesome grasses encompass Bermuda, Johnson, rye and Kentucky bluegrass.

Monitoring pollen levels helps determine optimal times for outdoor activities. The American Academy of Allergy Asthma and Immunology maintains tracking through counting stations nationwide, with data accessible on their website and through email alerts.

Prevention through reduced exposure remains the primary defense against allergies. Keep vehicle and home windows sealed, even during pleasant weather.

Dr. James Baker, a University of Michigan allergist, recommends wearing long sleeves outdoors to prevent pollen contact with skin and reduce allergic responses. “It also provides some sun protection,” he added.

Upon returning indoors, change clothing immediately and shower daily to eliminate all pollen, including from hair. For those unable to wash hair daily, covering it with hats or scarves when outside helps. Avoid bringing outdoor clothing into bed, as pollen will transfer.

Medical experts suggest rinsing eyes and nasal passages with saline solution to remove pollen particles. Face masks used during the pandemic can also provide allergy protection, though they won’t address eye-related symptoms.

Nasal sprays available without prescription rank among the most effective seasonal allergy treatments, according to specialists.

However, improper usage often causes nasal irritation, explains Dr. Kathleen May, an allergist at Augusta University in Georgia. She recommends directing the spray nozzle toward your ear rather than straight up the nostril.

Oral antihistamines including Claritin, Allegra and Zyrtec provide benefits but may work more slowly since they’re ingested rather than applied directly, experts note.

When allergy symptoms significantly impact daily life by disrupting sleep or affecting work or school performance, consulting an allergist becomes advisable. Specialized medications can retrain the immune system to reduce overreactions to allergens.

Certain allergy remedies promoted on social media or by celebrities, such as consuming local honey to build pollen tolerance, lack scientific support.

Dr. Shyam Joshi from Oregon Health and Science University explains this occurs “because the flowers that bees pollinate typically don’t contain the airborne pollen that causes allergy symptoms.”

Climate change contributes to milder winters and extended growing periods, creating more opportunities for airborne pollen and resulting in prolonged, more severe allergy seasons.

The previous year marked one of the most intense allergy seasons recorded, especially throughout the southeastern United States.

Scientific research demonstrates that maintaining a positive outlook can extend your lifespan, boost professional achievements, and decrease the likelihood of developing chronic health conditions. NPR’s Life Kit program has compiled practical guidance to help people cultivate a more optimistic mindset.

The benefits of positive thinking extend beyond just feeling good, according to researchers who have documented measurable improvements in both physical health and career advancement among those who practice optimism.

Most young men from Generation Z have embraced betting as a common activity, placing wagers on everything from sporting events to pop culture outcomes and political races. This demographic is also confronting serious negative impacts from their wagering habits.

The widespread participation in betting among this age group spans multiple categories, with young men frequently placing bets on sports competitions, entertainment industry events, and electoral contests. Despite the popularity of these activities, members of this generation are simultaneously dealing with the harmful effects that can result from gambling behavior.

Medical professionals across the country are witnessing a troubling trend as parents increasingly decline standard preventive treatments for their newborns, extending beyond vaccine hesitancy to other routine medical interventions.

Dr. Tom Patterson, an Idaho pediatrician with nearly three decades of experience, recently observed that half of the newborns he examined on one particular day didn’t receive vitamin K injections – a standard treatment administered for decades to prevent potentially fatal bleeding disorders. On another recent occasion, more than 25% of babies missed this crucial intervention due to parental refusal.

“When you look at a child who’s innocent and vulnerable — and a simple intervention that’s been done since 1961 is refused — knowing that baby’s going out into the world is super worrisome to me,” Patterson explained.

Healthcare providers nationwide express alarm as skepticism driven by increasing anti-science attitudes and medical distrust spreads beyond vaccination debates to encompass other established, routine preventive treatments for infants.

Research published in the Journal of the American Medical Association examined over 5 million births across the country, revealing that vitamin K injection refusals nearly doubled from 2.9% to 5.2% between 2017 and 2024. Additional studies indicate parents who reject vitamin K shots are significantly more likely to also refuse hepatitis B vaccinations and eye ointments designed to prevent potentially blinding infections for their newborns. Birth vaccination rates have declined recently, with physicians confirming increased parental refusal of eye medications.

Dr. Kelly Wade, a Philadelphia neonatologist, acknowledged parental concerns while highlighting the confusion they face. “I do think these families care deeply about their infants,” Wade said. “But I hear from families that it’s hard to make decisions right now because they’re hearing conflicting information.”

Countless social media posts challenge medical recommendations for proven safe and effective treatments like vitamin K injections and eye ointments. Political developments have also influenced medical decision-making, with the Trump administration frequently challenging established scientific consensus. A federal advisory committee, whose members were selected by Health Secretary Robert F. Kennedy Jr. – a prominent anti-vaccine advocate prior to his government role – voted to eliminate the long-standing recommendation for universal hepatitis B immunization immediately following birth. A federal judge temporarily halted all decisions from the restructured committee on Monday.

Dr. David Hill, a Seattle pediatrician and researcher, identified a common misconception linking anti-vaccine beliefs with resistance to other newborn protective measures: the false belief that natural approaches always surpass medical interventions.

“Nature will allow 1 in 5 human infants to die in the first year of life,” Hill explained, “which is why generations of scientists and doctors have worked to bring that number way, way down.”

Newborns naturally have insufficient vitamin K levels, creating vulnerability because their digestive systems cannot produce adequate amounts until they begin consuming solid foods around six months of age.

Dr. Kristan Scott from Children’s Hospital of Philadelphia, who led the JAMA research, emphasized the importance of this intervention. “Vitamin K is important for helping the blood clot and preventing dangerous bleeding in babies, like bleeding into the brain,” Scott stated.

Prior to routine injections becoming standard practice, approximately 1 in 60 babies experienced vitamin K deficiency bleeding, which can also impact the digestive system. While this condition is now uncommon, studies demonstrate that newborns who don’t receive vitamin K shots face 81 times higher risk of developing severe bleeding compared to those who receive the treatment.

Hill has witnessed the devastating consequences firsthand. “I cared for a toddler whose parents had chosen that risk,” the Seattle physician recalled. The child suffered what was essentially a stroke as a newborn, resulting in severe developmental delays and ongoing seizures.

During a February gathering of the Idaho chapter of the American Academy of Pediatrics, physicians reported knowledge of eight fatalities from vitamin K deficiency bleeding within the state during the previous 13 months, according to Patterson, who serves as chapter president.

Infections prevented by other standard newborn treatments can also result in serious consequences. Erythromycin eye ointment provides protection against gonorrhea that may be transmitted during delivery and can potentially cause blindness without treatment. The hepatitis B vaccination prevents a disease that may result in liver failure, liver cancer, or cirrhosis.

Even when pregnant women undergo testing for gonorrhea and hepatitis B, Dr. Susan Sirota, a Highland Park, Illinois pediatrician, notes that no test achieves perfect accuracy, and infections may occur after testing. Regardless of timing, mothers risk transmitting infections to their children.

Parents offer various explanations for declining preventive treatments, including concerns about potential complications and reluctance to cause newborn discomfort.

Dr. Steven Abelowitz, who founded Ocean Pediatrics in Orange County, California, encounters diverse reasoning. “Some will just say they want more of a natural birth philosophy,” Abelowitz observed. “Then there’s a ton of misinformation. … There are outside influences, friends, celebrities, nonprofessionals and political agendas.”

Abelowitz serves a community with roughly equal Republican and Democratic populations. “There’s more mistrust from the conservative side, but there’s plenty on the more liberal side as well,” he noted. “It’s across-the-board mistrust.”

Social media platforms amplify the problem, spreading false information and promoting unregulated vitamin K drops that medical professionals warn babies cannot absorb effectively.

Healthcare providers across multiple states report that parents who refuse vitamin K injections frequently decline other interventions as well. Sirota encountered a family in Illinois that rejected heel stick testing to monitor glucose levels for a baby at high risk for potentially life-threatening low blood sugar.

Treatment refusals aren’t entirely new. Wade has observed them for two decades in Philadelphia, but until recently, such cases were uncommon.

Twelve years ago, Dana Morrison, currently working as a Minnesota doula, rejected the vitamin K shot for her newborn son, choosing oral drops as an alternative. “It came from a space of really wanting to protect the bonding time with my baby,” Morrison explained. “I was trying to eliminate more pokes.”

Her daughter’s birth several years later presented complications, leaving the infant with a bruised leg. Morrison chose the vitamin K injection for her daughter. Looking back with current knowledge, she would have made the same choice for her son.

Medical professionals aim to change perspectives through individual conversations, beginning with respectful dialogue.

“If I walk into the room with judgment, we are going to have a really useless conversation,” Hill emphasized. “Every parent I serve wants the best for their children.”

When parents express doubts about vitamin K shots, Dr. Heather Felton focuses on addressing their specific worries. She explains the treatment’s purpose and the risks of refusing it. Most families ultimately choose to proceed with the injection, according to Felton, who hasn’t observed an increase in refusals.

“It really helps that you can take that time and really listen and be able to provide some education,” explained Felton, who practices pediatrics at Norton Children’s in Louisville, Kentucky.

In Idaho, Patterson frequently addresses misconceptions. Some parents agree to vitamin K shots once they learn the treatment isn’t a vaccine, for instance.

These discussions require significant time investment, particularly since hospital physicians typically encounter parents they haven’t previously treated in their practices.

However, doctors willingly dedicate this time if it might protect infant lives.

Patterson concludes each parental discussion with a personal appeal. “I end every discussion with parents with this: ‘Please understand at the end of the day, I’m passionate about this because I have the best interest of children in my mind and heart,’” Patterson shared. “I understand this is a hot topic, and I don’t want to disrespect anybody. But at the same time, I’m desperately saddened that we’re losing babies for no reason.”

When Elisabeth Bradley started college, she became motivated to begin strength training after following a woman’s fitness journey on social media, watching her progress one barbell at a time.

However, Bradley discovered she was the sole female in San Diego State University’s weight room.

“I felt like I stuck out a lot, and I just thought, ‘OK, I’m gonna look dumb,’” she says. Feeling overwhelmed by a space filled with grunting, muscular men, she relocated to the cardio section, reflecting the experience of numerous women who steer clear of free weights and strength equipment for different reasons.

As evidence grows regarding resistance training benefits, professionals believe several changes are needed in gym environments to attract more women.

Michelle Segar, a behavioral scientist at the University of Michigan who researches exercise patterns, explained that creating more welcoming environments and improving women’s familiarity with weights would encourage greater participation. Increased representation would then help more women stick with their routines.

The National Institutes of Health advises everyone — both men and women — to engage in resistance training a minimum of twice weekly. This encompasses various activities requiring physical force, including weight machines, resistance bands, or bodyweight movements like pushups and squats.

Research has shown resistance training helps prevent cardiovascular disease, enhances long-term mobility and reduces blood pressure, according to Brad Schoenfeld, an exercise science professor at Lehman College in New York City. Some studies indicate women may gain even greater benefits than men from weight training since it helps prevent osteoporosis and age-related muscle deterioration, conditions women face higher risks for developing, he explained.

“The bottom line is, resistance training is a cure for all sorts of issues,” Schoenfeld said.

Daisy Arauza, a 30-year-old mother of two from Menifee, California, currently does Pilates and cardio workouts at home using videos and online guides, and wants to purchase a gym membership to help with strength building and weight management.

However, she struggles with confidence issues and doesn’t feel knowledgeable enough about weights and proper gym behavior.

“I have a lot of self-consciousness because of how my body looks right now. When you think of the gym, you think about people that are already more fit. And so it feels like I have to make myself fit into this mold before I can feel comfortable being in a gym setting working out in front of other people,” she said.

A persistent stigma still exists around women lifting weights, Bradley noted. After years of being told that thinness is the ideal goal, some incorrectly assume strength training will create a bulky appearance.

Schoenfeld explained that most women shouldn’t worry about developing excessive muscle mass because gaining significant amounts is difficult for anyone — particularly women, who possess lower levels of testosterone, the muscle-building hormone. If someone dislikes their results, reducing training intensity is simple, he noted: “It’s very, very easy to lose muscle.”

Several months following her disappointing first experience, Bradley discussed her strength-training aspirations with a male weightlifter from her dormitory, who taught her bodybuilding fundamentals. This encouragement motivated her to establish Girl Gains, a female weightlifting organization that now operates dozens of chapters at universities nationwide.

“Other things get shoved down our throats, like Pilates and cardio and yoga, but they complement each other,” Bradley said. “Being stronger in the gym is going to help you progress in Pilates. Having muscle is going to help make you a faster, better runner.”

Women beginning strength training should receive empowering and realistic guidance, supporters emphasize.

While complementary introductory sessions can be helpful, superficial instruction from trainers in revealing clothing won’t be effective, Segar warned.

“Most women have tried to achieve the perfect body for decades, and it only leads to a sense of failure,” she said. Rather than concentrating on how exercise makes them feel, they’re worrying about others’ perceptions.

Women who discover community in weight rooms collaborate on personal goals, becoming stronger and challenging themselves, Bradley observed. “One of the things we always say is, ‘The gains look good on you.’”

Some women discover they can concentrate better on their workouts without men present.

At the women-only Goddess Gym in Peterborough, England, Charlie Sturgeon reported feeling happier than she did in co-ed facilities where she experienced “some quite weird experiences where people would just stare, pull faces, make comments. And here, with being women only, it just feels like there’s a sense of community.”

Some fitness centers attempt to accommodate women better by providing on-site childcare services.

Michelle Kozak of Phoenix, who has two young children, terminated her membership when her gym discontinued child care services.

She also feels uncomfortable with intense gym culture.

“I don’t want to make the gym my entire personality,” she said. “I just want to have some time to prioritize being healthy.”

Federal health authorities have announced the withdrawal of approximately 90,000 bottles of children’s ibuprofen from store shelves after customers discovered concerning foreign materials in the liquid medication.

The Food and Drug Administration published details about the recall involving Taro Pharmaceuticals’ Children’s Ibuprofen Oral Suspension on their website. According to the company’s information, this berry-flavored liquid medicine is designed for youngsters between 2 and 11 years old.

Federal officials explained in their announcement that the recall began this month following consumer complaints about “a gel-like mass and black particles in the product.” Health regulators have classified this recall as having a “remote” likelihood of causing severe harm or adverse health effects to users.

The recalled medication was produced in India by Strides Pharma Inc., a manufacturer that creates both generic medications and non-prescription drugs for companies across the United States and internationally. According to FDA documentation, Strides Pharma initiated the product withdrawal.

As of Friday morning, representatives from both Strides Pharma and Taro Pharmaceuticals had not provided responses to media inquiries about the recall.

A deadly meningitis B outbreak in Kent, England has claimed two lives and infected 29 people, creating widespread panic that has led to severe vaccine shortages and renewed debate over Britain’s immunization policies.

The crisis has prompted young adults across southeastern England and other regions to seek immediate vaccination, overwhelming pharmacy supplies and forcing government intervention to address the shortage.

Those who may have come into contact with infected individuals can receive both the vaccine and preventive antibiotics through the UK Health Security Agency via university locations, medical clinics, and family doctors.

However, private sector demand has skyrocketed as concerned citizens seek protection, creating unprecedented strain on available supplies.

“Pharmacies have been inundated with requests for MenB vaccines in recent days,” stated the National Pharmacy Association, which represents 6,000 independent pharmacies across Britain.

Major pharmacy chains Boots and Superdrug have both issued shortage warnings and established online waiting lists for the vaccine. Boots announced efforts to secure additional supplies while prioritizing high-demand areas, particularly Kent.

The government responded Thursday by releasing 20,000 meningitis B vaccine doses from NHS reserves to help alleviate private market shortages, though the National Pharmacy Association believes this won’t satisfy current demand levels.

Two vaccines are available: Bexsero, manufactured by British company GSK and used by the NHS, and Trumenba, produced by American pharmaceutical giant Pfizer. Both cost approximately 200 pounds ($267) when purchased privately.

Currently, British teenagers don’t receive routine meningitis B vaccination, unlike many other nations. The disease attacks protective membranes surrounding the brain and spinal cord.

Meningitis B represents one bacterial strain causing the condition, though other bacterial types and viral infections can also trigger meningitis. Warning signs include fever, drowsiness, and vomiting, with the disease potentially becoming life-threatening rapidly.

Britain has administered meningitis B shots to infants since 2015, as babies face the highest risk. Teenagers receive a different vaccine targeting other strains.

“I can understand people suddenly wanting the vaccine,” commented Brendan Wren, professor and co-director of the London School of Hygiene and Tropical Medicine Vaccine Centre, noting no harm comes from receiving the shot.

Nevertheless, Wren emphasized that antibiotics remain the optimal choice for those fearing exposure, as antibiotics work almost immediately while vaccine immunity requires a full month to develop from the two-dose series.

The outbreak has intensified discussions about expanding meningitis B vaccine access to teenagers, who represent the second-highest risk group.

“There is a gap in the NHS vaccination schedule… there’s a strong moral case for stepping in,” declared Tom Nutt, chief executive of Meningitis Now, Britain’s largest meningitis charity.

Following the Kent outbreak, Health Secretary Wes Streeting has requested the Joint Committee on Vaccination and Immunisation to reassess meningitis B vaccine eligibility within the NHS system.

However, Streeting also stated that private vaccine purchases weren’t necessary, as at-risk individuals receive coverage through the UKHSA campaign.

Adam Finn, professor emeritus of pediatrics at the University of Bristol and JCVI member for other vaccines, explained that healthcare intervention recommendations like vaccines rely on “cost-benefit” analyses.

While the 29 Kent cases represent an unusually high number, Finn suggested this alone wouldn’t likely alter JCVI’s position unless similar outbreaks follow.

He said the JCVI would “follow the evidence-based methods they always use to ensure that we all obtain the best value possible from the resources allocated to the NHS,” while acknowledging this approach cannot compensate for the suffering experienced by meningitis victims.

Federal health authorities gave the green light Thursday to a more powerful formulation of the widely-used weight-loss medication Wegovy, offering hope for enhanced results among patients seeking to shed excess pounds.

The U.S. Food and Drug Administration authorized a 7.2-milligram weekly injection from Denmark-based pharmaceutical company Novo Nordisk. This represents a significant increase from the current maximum strength of 2.4 milligrams per dose.

The enhanced formulation received expedited consideration under the FDA’s accelerated assessment pathway. Officials completed their review within 54 days of accepting the application, according to an agency announcement.

Novo Nordisk plans to make the stronger dose available at American pharmacies beginning in April, with pricing details to be revealed at that time.

European health regulators had previously authorized the higher-strength version in February.

Research participants using the enhanced formulation, branded as Wegovy HD, achieved approximately 19% body weight reduction, equivalent to nearly 47 pounds, compared to roughly 16% weight loss or 39 pounds with the standard dose over a 17-month period.

Scientists developed the stronger version because while the existing 2.4-milligram injection proves effective for many patients, “some individuals do not reach their therapeutic goals” at the current strength, according to findings published in Lancet Diabetes & Endocrinology.

The FDA previously approved an oral Wegovy tablet in December, containing 25 milligrams of the active ingredient semaglutide to ensure proper absorption through the digestive tract.

Dr. Jody Dushay, who specializes in endocrinology and obesity treatment at Harvard Medical School, praised the approval of the stronger injection.

The enhanced dose “may be especially helpful for people” who tolerate the current version well but “have had suboptimal weight loss,” she explained via email. She noted it could also benefit individuals who don’t respond strongly to Eli Lilly’s competing obesity treatment Zepbound.

However, digestive issues including nausea, vomiting and constipation affected more than 70% of patients taking the higher dose, compared to over 60% using the standard strength and approximately 43% receiving inactive treatment, study data revealed.

Additionally, a condition causing uncomfortable skin sensations like burning, stabbing or electric shock-like feelings occurred in roughly 23% of higher-dose patients versus 6% taking the standard dose and under 1% receiving placebo treatment.

Severe complications were documented in nearly 7% of participants using the 7.2-milligram dose, compared to about 11% taking the 2.4-milligram version and roughly 5% receiving inactive treatment.

Dr. Dushay observed that jumping from 2.4 milligrams to 7.4 milligrams represents “quite a big jump,” particularly without an intermediate strength option.

“It will be important to see if in the real world, versus in a clinical study, side effects are any worse,” she cautioned.

Danish pharmaceutical giant Novo Nordisk announced Thursday that federal health regulators have given the green light to an increased strength version of its weight loss medication Wegovy.

The Food and Drug Administration’s approval covers the higher-dose formulation for helping patients shed excess pounds and keep the weight off over extended periods, according to the company’s announcement.

The enhanced dosage represents an expansion of treatment options for the popular weight management drug that has gained significant attention in recent years.

Priscilla Brown faces an impossible choice each day: take her full diabetes medication or have enough money for gas to get to work. The 48-year-old Orlando truck dispatcher sometimes reduces her insulin to just half or one-third of what doctors prescribed, trying to make it last longer.

“Sometimes I don’t even take my medicine,” Brown explained. “It’s so much with insurance, it’s crazy.”

Brown’s struggle reflects a nationwide crisis revealed in new research from KFF, a healthcare nonprofit. Their survey found that roughly 4 out of 5 Americans who renewed their Affordable Care Act insurance report facing steeper healthcare expenses this year, with approximately half describing their costs as significantly higher.

The primary driver behind these climbing expenses was the December 31st end of expanded tax credits that had helped reduce premiums for most marketplace participants.

The financial strain is forcing difficult decisions across the country. Among the 1,117 surveyed Americans who held ACA marketplace insurance in 2025 – including those who dropped or switched coverage – approximately 55% plan to reduce spending on groceries and essential household items to manage their medical expenses.

Congressional Democrats had pushed to maintain the pandemic-era subsidies last year but encountered resistance from Republican leaders. By January, efforts toward a bipartisan solution collapsed, leaving roughly 23 million ACA participants without assistance as they confronted increased premiums or difficult choices to cancel or downgrade their plans.

The February and March survey, which reconnected with participants from a previous year’s study to track their current insurance challenges, reveals how the ongoing congressional stalemate continues affecting ordinary Americans while many federal legislators have shifted focus to other issues.

Brown’s situation illustrates the dramatic change. Last year, she paid nothing for her health insurance premiums. Her current plan costs $17 monthly and includes a higher deductible.

This week, Brown discovered her medication refill would exceed $150 and “almost passed out.” She put only half a tank of gas in her car, saving money for her prescriptions.

The survey shows widespread anxiety about unexpected medical bills. Roughly three-quarters of people who had ACA coverage last year express significant concern about affording emergency treatment or hospital stays, while about half worry about routine doctor visits or prescription medications.

Most previous enrollees – about 70% – maintained ACA health insurance, though this includes roughly 30% who switched plans within the marketplace. Meanwhile, approximately 20% became eligible for employer-provided coverage, Medicare, Medicaid, or bought insurance outside the ACA marketplace, which typically offers less comprehensive benefits.

About 10% of last year’s participants dropped coverage entirely and now lack insurance, according to the poll.

Eric LeVasseur, a 63-year-old Seal Beach, California software developer, joined that uninsured group. When he discovered his mid-level silver plan would nearly triple to $1,200 monthly, “it was not something my budget could absorb,” he said.

Approximately 70% of returning ACA enrollees experiencing higher costs heavily blame health insurance companies, while just over half place significant blame on Republican lawmakers, President Donald Trump, and pharmaceutical companies. About one-third heavily blamed Congressional Democrats or hospitals, while roughly 10% placed this level of responsibility on doctors or employers.

Survey participants who identified with a political party and experienced cost increases overwhelmingly blamed opposing party lawmakers.

James Mako, a Boca Raton, Florida engineer and political independent, holds the Republican Party responsible. His $500 monthly premiums were set to double for his silver-level ACA plan this year, forcing him to downgrade to a bronze-level plan with higher out-of-pocket costs.

Mako remains skeptical of Republican proposals to address the problem, such as directing funds into health savings accounts.

“I think they’re just sales gimmicks,” he stated. “The subsidies should be back.”

The KFF survey was conducted February 12 through March 2, 2026, among 1,117 U.S. adults who held Marketplace insurance in 2025, using samples from two probability-based panels. All participants had taken part in the 2025 KFF Marketplace Survey and were recontacted for this follow-up study. The margin of sampling error for the complete sample is plus or minus 3.8 percentage points.

Robert F. Kennedy Jr., serving as the nation’s health secretary in the Trump administration, has been making sweeping statements about nutrition’s power to treat serious medical conditions as part of his “Make America Healthy Again” initiative.

Beyond his basic message encouraging Americans to “eat real food” for disease prevention, Kennedy has made more dramatic assertions during recent public appearances. He has stated that dietary changes can “cure” conditions like schizophrenia and diabetes, and claimed people can eliminate bipolar disorder diagnoses through nutrition alone. Medical researchers are pushing back, saying these statements go far beyond what current scientific evidence supports.

“Food is medicine, and you can heal yourself with a good diet,” Kennedy declared during an appearance on comedian Theo Von’s “This Past Weekend” podcast in February.

While Kennedy’s emphasis on nutrition’s health benefits has gained some bipartisan backing, public health experts are concerned about his tendency to misinterpret scientific studies. They argue this pattern mirrors his controversial approach to vaccine research, which has drawn criticism from medical professionals.

Kayla Hancock, who leads a public health initiative at the advocacy organization Protect Our Care, characterized Kennedy’s approach as “incredibly careless and irresponsible” when discussing health matters.

Dr. Theresa Miskimen Rivera, who heads the American Psychiatric Association, expressed concern that Kennedy’s language might encourage patients to abandon proven medical treatments in favor of dietary interventions alone.

“The concern always is that people can have hope and they might interpret that as, ‘Well, I don’t need medication. I do not need treatment. I just need to follow the diet,’” Rivera explained.

During a February address at Tennessee’s state capitol, Kennedy referenced research by Dr. Christopher Palmer, a Harvard Medical School scientist who documented two schizophrenia patients experiencing symptom improvement while following a ketogenic diet high in fats and low in carbohydrates.

Kennedy claimed that Palmer had “cured schizophrenia using keto diets.”

Palmer has disputed this characterization, telling The Associated Press that “as much as I wish we had cures for mental illness or other chronic diseases, it is important that we use more precise language.” Palmer said he prefers using the term “remission” rather than “cure.”

In the same Tennessee speech and later during an appearance on Joe Rogan’s podcast, Kennedy mentioned research “where people lose their bipolar diagnosis by changing their diet.” He also claimed “there’s a big paper about to come out” demonstrating these results.

Kennedy’s representative Andrew Nixon said these statements were based on “a growing body of research,” including a UCLA study examining ketogenic diet effects on teenagers with bipolar disorder.

However, that UCLA research is still enrolling participants and won’t conclude until March 2027, according to federal records. Any published results would come months later.

Rivera emphasized that Kennedy’s assertions overstate existing evidence. She noted that studies examining ketogenic diets’ impact on mental health have been limited in scope, often lacking control groups for comparison.

“At this point, it’s premature. We cannot draw definitive conclusions,” Rivera stated. “There is not enough evidence to recommend a specific diet or as a standalone, without medication such as antipsychotics or mood stabilizers.”

Palmer acknowledged that research into dietary interventions for psychiatric conditions is expanding, with 20 controlled clinical trials currently investigating ketogenic diets for severe mental illness. Results from two studies are expected within the year.

While Palmer expressed enthusiasm about diet as a potential therapy for serious psychiatric disorders, he stressed the importance of medical supervision.

“I want to implore patients: Please do not stop your medications on your own,” he urged. “Please do not even try a ketogenic diet on your own as a treatment for schizophrenia or bipolar disorder.”

Kennedy’s podcast statement that “most diabetes can be cured through diet” has also faced scrutiny from medical professionals.

Dr. Willa Hsueh, an endocrinologist and researcher at Ohio State University, explained that Type 1 diabetes, which is an autoimmune condition, cannot be treated through diet alone. While proper nutrition and exercise are crucial for managing Type 2 diabetes, she said using these methods alone to reverse the condition is challenging.

“The secretary is not wrong that it can work,” Hsueh acknowledged. “But it’s not common for people to cure themselves … by diet alone.”

Some medical experts have supported Kennedy’s diabetes claims. Dr. Dariush Mozaffarian, a cardiologist who directs the Food is Medicine Institute at Tufts University, said proper nutrition could help “most individuals” with Type 2 diabetes reduce blood sugar levels, reverse symptoms, and potentially eliminate their need for medication.

“Whether you consider that a cure or remission, that’s medical speak, right?” Mozaffarian noted.

While acknowledging that Kennedy isn’t “always perfectly precise in the terminology and there could be risks to that,” Mozaffarian said he appreciates the high-level attention being given to diet’s role in managing chronic diseases.

“I’d rather exaggerate and get some attention and action than keep doing what we’re doing, which is have millions of Americans suffering from diet-related diseases,” Mozaffarian said.

Mark Gorton, who leads the Kennedy-affiliated MAHA Institute, said nutrition has been “an incredibly overlooked area in our medical system for decades,” though he wasn’t familiar with the specific studies Kennedy mentioned.

“I think to the extent that it is possible, we should be prioritizing focusing on diet and getting back to living healthy rather than taking sick people and medicating them forever, which is the current way our system works,” Gorton explained.

Kody Green, a mental health advocate living with schizophrenia, expressed support for healthy eating while emphasizing his need for psychiatric medications. He worried that Kennedy’s statements might discourage schizophrenia patients from trying treatments that already face stigma.

“For some people, maybe food can help with the issues they have, but schizophrenia is a very serious mental illness,” Green said. “Until further research is done, making claims like that can be really dangerous to people in my community.”

British health authorities announced Thursday that a meningitis outbreak affecting southeastern England remains uncontained, with officials confirming seven additional cases of the deadly disease.

The UK Health Security Agency reported the total confirmed cases has climbed to 27, impacting pupils at four educational institutions in Kent County plus one student in London. Two fatalities have been linked to the outbreak.

Dr. Anjan Ghosh, Director of Public Health at Kent County Council, addressed the situation during a BBC Radio interview, stating: “We are not in the position yet to say definitively that it’s been contained.” He emphasized that officials must first eliminate the possibility of secondary transmissions.

The victims include a 21-year-old University of Kent student and a teenager attending school in Faversham. Under normal circumstances, Britain typically records approximately 350 meningitis cases annually, or roughly one case daily, based on government data.

Medical professionals warn that meningococcal meningitis and septicaemia present with various warning signs including elevated body temperature, severe headaches, accelerated breathing patterns, fatigue, chills, nausea, and extremities that feel cold to the touch. Septicaemia may also produce a distinctive rash that remains visible when pressure is applied with a glass.

College and university students face heightened risk due to their close contact with fellow students in dormitory and classroom settings.

The UK’s leading pharmacy chain, Boots, reported experiencing “unprecedented demand” for meningitis B vaccinations, leading to supply shortages nationwide.

Despite the outbreak, the European Centre for Disease Prevention and Control maintains that the threat of invasive meningococcal disease to Europe’s general population remains “very low.”

Pharmaceutical company Eli Lilly announced Thursday that its experimental weight loss medication demonstrated significant improvements in blood sugar control during advanced clinical testing, as the company seeks to strengthen its position in the competitive obesity treatment market.

The booming weight loss drug industry has attracted numerous developers competing against established treatments like Novo Nordisk’s Wegovy and Lilly’s own Zepbound. Companies are investing heavily in advanced therapies that could provide more effective, longer-lasting, or faster weight reduction results.

The experimental medication, called retatrutide, was evaluated in people with type 2 diabetes who struggled to manage their blood sugar through diet and exercise alone. Study participants had been living with diabetes for an average of two and a half years.

Throughout the 40-week study period, retatrutide lowered A1C levels—a standard measurement of blood sugar over time—by 1.7% to 2.0% on average across different dosages. In comparison, participants receiving a placebo saw only a 0.8% average reduction.

As an additional benefit, patients using the medication experienced weight loss averaging up to 16.8% of their body weight.

The company reported that adverse effects were consistent with what researchers typically observe in weight loss studies, primarily digestive problems including nausea, diarrhea, and vomiting.

Earlier research showed retatrutide helped participants achieve an average weight reduction of 28.7%, surpassing the performance of Lilly’s successful medication Zepbound.

Administered as a weekly injection, retatrutide works by copying the function of the GLP-1 hormone, which plays a role in managing blood sugar levels, slowing digestion, and reducing hunger.

The medication targets three different hormone receptors—GLP-1, GIP, and glucagon—which has earned it the informal name “triple G.” These triple-action weight loss treatments are anticipated to achieve superior results compared to earlier medications by simultaneously suppressing appetite, controlling blood sugar, and boosting calorie expenditure.

Lilly is simultaneously working on orforglipron, a weight loss medication in pill form, which the company anticipates launching in the second quarter of this year pending U.S. Food and Drug Administration approval.

A new study published in the World Happiness Report Thursday reveals that teenagers spending excessive time on social media platforms experience decreased mental wellbeing, with teenage girls facing the most significant impact.

The research comes as nations worldwide consider restricting children’s access to social platforms, following Australia’s groundbreaking decision in December to prohibit social media use for anyone under 16 years old.

The annual study analyzed information from Gallup polling data and additional research, with analysis conducted by an international research team headed by Oxford University in England.

While the study stopped short of proving a direct causal relationship, researchers combined multiple data sources including information from the OECD’s Programme for International Student Assessment to reach their conclusions about social media’s negative effects on youth happiness.

“The message coming through loud and clear is that we should try to put the social back into social media,” Professor of Economics at the University of Oxford Jan-Emmanuel de Neve, one of the editors of the World Happiness Report, told Reuters.

De Neve explained that content driven by algorithms, consumed passively, and dominated by influencers creates more harmful effects than platforms designed to foster genuine social connections between users.

The research specifically found that 15-year-old girls spending more than five hours daily on social platforms reported decreased life satisfaction when compared to peers who use these services less frequently, though researchers acknowledged the relationship between social media and mental health remains complicated.

Data from Gallup’s international polling revealed that young people under 25 in the United States, Canada, Australia and New Zealand have seen their life satisfaction scores plummet “dramatically” – dropping nearly a full point on a 10-point measurement scale during the past ten years.

Meanwhile, young people in other regions around the globe reported increased life satisfaction during this same timeframe.

Julie Ray, Gallup’s managing editor, suggested the disparity between English-speaking nations and other countries likely stems from broader societal factors affecting youth.

“Social support is one of the strongest predictors of wellbeing, and previous research shows that in some countries younger people report feeling less supported, which may help explain the pattern,” she told Reuters by email.

Medical device manufacturer Stryker experienced a cyber attack last week that has resulted in surgical delays for certain patients, according to a report from Bloomberg News released Wednesday.

The digital security breach temporarily disrupted Stryker’s operations, specifically affecting their capacity to provide customized medical equipment and supplies. A company representative told Bloomberg that “as a result, some patient-specific cases have been rescheduled” due to the inventory delivery problems caused by the system outage.

When contacted by Reuters for additional details about the incident, Stryker had not yet provided a response.

A tortilla manufacturing company based in Mission, Texas has initiated a product recall for two sweet treats that contain hidden allergens not listed on their labels.

The recall from Mama Grande Tortilla Factory affects their Gorditas de Azucar and Doraditas de Azucar products, which were found to contain wheat and soy ingredients that weren’t disclosed on packaging.

Health officials warn that consumers with wheat or soy allergies face potential serious or life-threatening reactions if they eat these products. The undeclared allergens pose significant health risks for those with sensitivities to these ingredients.

The company is working to remove the affected products from distribution while investigating how the unlabeled allergens ended up in the sweet treats.

ORLANDO, Fla. — A woman occupying Room 373 at a Florida hospital has sparked an unusual legal battle by refusing to leave five months after doctors cleared her for discharge.

Tallahassee Memorial Healthcare filed a lawsuit this month against the patient, claiming she has remained in her hospital room since receiving discharge papers last October. Hospital officials are asking a state judge to issue an injunction forcing the woman to leave and giving the county sheriff’s department authority to remove her if needed.

Hospital administrators say the woman’s extended stay is interfering with their ability to care for other patients who need the room.

“Defendant’s continued occupancy prevents use of the bed for patients needing acute care,” the hospital stated in court documents.

The lawsuit reveals that the woman was initially hospitalized for medical treatment before receiving an official discharge order on October 6, when doctors determined she no longer required intensive hospital care. Hospital staff have made multiple attempts to work with her family members to arrange her departure and even offered help with transportation to get required identification documents, according to the legal filing.

Rachel Givens, the hospital’s attorney, declined to provide additional details when contacted Wednesday. The hospital also did not respond to questions about what identification the patient needed. The court documents don’t specify her original medical condition, her hospital charges, or explain how she managed to remain at the facility for over five months after being medically cleared to leave.

The patient is representing herself in the case and no lawyer has been assigned to her. Attempts to reach her were unsuccessful, as phone numbers found in public records were no longer in service, and calls to her hospital room went unanswered.

A virtual court hearing regarding the lawsuit is set to take place at the end of this month.

Federal law requires hospitals that accept Medicare funding to provide emergency treatment to stabilize any patient who arrives at their emergency department with a medical emergency, regardless of their insurance status or ability to pay under the Emergency Medical Treatment and Labor Act. The Centers for Medicare & Medicaid Services can investigate hospitals for violations of this requirement.

According to federal guidelines, patients may be discharged once medical staff determine that any additional care can be handled on an outpatient basis, “provided the individual is given a plan for appropriate follow-up care as part of the discharge instructions,” the federal agency states in its operations manual.

A groundbreaking research study has revealed that the coronavirus pandemic claimed significantly more lives than official records show during its first two years in the United States.

Researchers utilizing artificial intelligence technology determined that roughly 155,000 COVID-19 fatalities went unrecorded between 2020 and 2021, beyond the 840,000 deaths officially documented on death certificates during that period. This suggests approximately 16% of coronavirus deaths during those critical years were never officially counted.

The findings, released Wednesday in Science Advances journal, align closely with previous research on pandemic mortality rates. However, this new investigation went further by identifying specific patterns among the unreported deaths.

The study found that unrecorded fatalities disproportionately affected Hispanic individuals and other communities of color, particularly during the pandemic’s initial months. These deaths were concentrated in certain Southern and Southwestern states, including Alabama, Oklahoma, and South Carolina.

“People on the margins continue to die at disproportionate rates because they can’t access care,” explained Steven Woolf, a researcher at Virginia Commonwealth University who was not part of the study team.

University of Minnesota researcher Elizabeth Wrigley-Field, one of the study’s authors, noted that while hospitals consistently tested patients for COVID-19, many individuals who became ill and died at home or in other non-hospital settings never received testing. This was especially common early in the pandemic when home testing options were scarce or unavailable.

The research also highlighted problems with America’s death investigation system. In many regions, elected coroners without specialized medical training handle death investigations, unlike trained medical examiners. Some studies suggest political beliefs may have influenced whether families sought COVID-19 testing or whether coroners pursued posthumous coronavirus testing.

“Our antiquated death investigation system is one key reason why we fell short of accurate counts, particularly outside of big metropolitan areas,” stated Andrew Stokes from Boston University, the study’s lead author.

According to Centers for Disease Control and Prevention records, more than 1.2 million Americans have died from COVID-19 since the pandemic began in early 2020, with over two-thirds of those deaths occurring in 2020 and 2021.

The death count has been a source of ongoing controversy, with false social media claims suggesting COVID-19 fatalities were exaggerated. Former President Donald Trump amplified these disputes in August 2020 by sharing a post claiming only 6% of reported deaths were actually caused by COVID-19, which Twitter subsequently removed.

The researchers acknowledged that the pandemic caused additional deaths beyond direct COVID-19 infections, including people who died from other conditions because hospitals were overwhelmed with coronavirus patients, and individuals who died from drug overdoses due to isolation and reduced access to treatment services.

However, Stokes and his team specifically focused on deaths directly caused by coronavirus infection. They employed machine learning technology to analyze death certificates of infected patients who died in hospitals, then applied those patterns to evaluate certificates of people who died outside hospitals from conditions like pneumonia or diabetes.

Woolf described the team’s application of machine learning as “intriguing,” noting that scientists are still developing their understanding of the capabilities and limitations of such research methods.

CANTERBURY, England — Two people have died and 20 others have contracted meningitis in an alarming outbreak that has gripped the University of Kent and surrounding areas in southeast England since last Friday.

British Health Secretary Wes Streeting called the situation in Kent County “unprecedented” on Wednesday, citing the rapid emergence of so many cases within just days. The death toll includes one university student and one pupil from a local school in the area.

Health authorities reported five additional infections on Tuesday, bringing the total to 20 confirmed cases. Officials are now distributing antibiotics and meningitis B vaccines to thousands of University of Kent students in Canterbury as a precautionary measure.

The disease affects the protective membranes surrounding the brain and spinal cord, caused by viral or bacterial infections. When bacterial meningitis develops, it can trigger a dangerous blood infection known as meningococcal sepsis, often appearing as a distinctive rash. Without immediate medical attention, the condition can prove fatal or result in limb amputations.

Britain typically sees approximately 350 meningitis cases annually, making it relatively uncommon. However, the infection spreads easily in crowded living situations like college dormitories. University students face heightened risk because the bacteria can remain inactive in people’s nasal passages or throats, then transmit through coughing, intimate contact, or sharing beverages.

Medical experts believe many infected individuals attended Club Chemistry in Canterbury between March 5-7. Healthcare providers nationwide have received instructions to provide antibiotics to anyone who visited the nightclub during those specific dates, along with University of Kent students.

“This is so that anyone who has traveled home, or away from Kent, can easily access this important preventative treatment close to them,” officials stated.

The recent COVID-19 pandemic has influenced local residents’ behavior, with many Canterbury area residents returning to mask-wearing and social distancing practices out of caution.

Medical teams have administered over 2,500 antibiotic doses, including treatments for Club Chemistry patrons. The meningitis B vaccination is also available, though most current university students wouldn’t have received it since it only joined Britain’s standard childhood immunization schedule in 2015. Some students may have obtained private vaccinations.

The U.K. Health Security Agency reports adequate vaccine supplies exist, but private pharmacies are experiencing difficulty securing doses for individuals seeking to pay out-of-pocket.

Case numbers may continue climbing since the infection’s incubation period extends up to two weeks. Researchers say it’s premature to determine whether this particular strain shows increased severity compared to others.

Despite student departures from Canterbury, Streeting expressed confidence the outbreak won’t spread nationally. “This is not currently a national incident,” he said.

Childhood immunization rates have plummeted in Michigan during the opening year of President Trump’s second term, according to new data analysis that shows the influence of vaccine-skeptic Health Secretary Robert F. Kennedy Jr. on American healthcare practices.

State records reveal that Michigan experienced a dramatic decrease in vaccination completion rates among toddlers, offering one of the first concrete glimpses into how Kennedy’s anti-vaccine stance is affecting public health nationwide. Michigan stands out among states for providing detailed monthly vaccination statistics, while comprehensive national figures won’t be available until later this year.

The data analysis examined how many toddlers received their complete series of seven essential vaccines – including measles, mumps and rubella (MMR), whooping cough, and hepatitis B shots – before turning three years old, which represents the federal health standard.

Between January 2025 and January of this year, completion rates dropped nearly three percentage points to 66.5%. This represents a decline roughly 13 times larger than typical annual variations seen over the past 18 years. Only the COVID-19 pandemic in 2020 and the 2008 financial crisis produced steeper drops in Michigan’s vaccination rates.

The analysis found that white children, who make up the largest demographic group, and Hispanic children experienced the most significant decreases. Public health experts, parents, researchers and community advocates interviewed across Michigan identified Kennedy’s persistent criticism of vaccines as the primary factor influencing white families, while Trump administration deportation efforts have deterred Latino families from visiting public health clinics.

Stanford University epidemiology professor Mathew Kiang expressed concern about the Michigan trends, noting the state’s size and demographic diversity make it a meaningful indicator.

“What’s happening there is almost certainly happening in other states,” Kiang said.

State data indicates that approximately 4,500 additional toddlers in Michigan now face heightened vulnerability to serious diseases due to the 2025 vaccination decline. These unvaccinated children also create risks for infants too young for immunization and adults with compromised immune systems, according to health authorities.

Oakland County epidemiologist Lauren Fink emphasized the broader implications in an email statement: “Even if the public health impact of one vaccine in one arm is unmeasurably small, every unvaccinated child is at risk.”

Kennedy has spent years promoting claims, contradicted by scientific research, that standard childhood immunizations cause autism and chronic illnesses while posing greater dangers than the diseases they prevent. Since assuming his role as the nation’s top health official, Kennedy has amplified these anti-vaccine messages through government channels, bringing views previously confined to specialized social media groups into mainstream federal communication.

Rachel Atwood, a long-time vaccine skeptic from western Michigan, noted the shift in public discourse: “People are becoming a little more open to questioning things because RFK Jr is pushing out information that has never been really readily available on mainstream media.”

Atwood supports Kennedy’s position that America dedicates excessive resources to infectious disease prevention rather than addressing chronic conditions like diabetes and obesity.

Kennedy has also restructured the childhood vaccination recommendation process, removing the existing national advisory board and installing members who share his perspectives. This new board recently guided federal officials to reduce recommended childhood immunizations despite lacking fresh evidence of vaccine harm. However, a federal judge blocked these changes Monday, agreeing with major medical organizations that argued the modifications would undermine vaccine confidence and reduce immunization rates.

Health and Human Services Department spokesman Andrew Nixon disputed Kennedy’s role in declining vaccination rates, instead blaming Michigan’s aggressive COVID-19 response, including school closures and mask requirements, for eroding public trust in health policies.

“Restoring confidence in public health, not repeating the mistakes of the pandemic era and failed policies from states like Michigan, is the path to stronger vaccination uptake over time,” Nixon said. He declined to address the decline among Hispanic children.

Dr. Natasha Bagdasarian, Michigan’s chief medical executive, distinguished the state’s 2025 immunization patterns from previous years, noting that vaccination rates had stabilized following the pandemic. Bagdasarian identified Kennedy’s rhetoric and policies as new factors creating doubt and confusion among families.

“Michigan is not failing,” Bagdasarian said. “I think we are being failed by some of the rhetoric that is being put out at the national level.”

The United States achieved measles elimination status in 2000 due to high vaccination coverage at that time. Increasing vaccine reluctance has gradually undermined this accomplishment.

Over the past year, America has confronted its most severe measles outbreaks in decades, beginning in Texas and continuing recently in South Carolina. At least two children have died and dozens required hospitalization, with most victims being unvaccinated. Michigan experienced surging whooping cough cases in 2024 that continued into 2025.

Rather than advocating widespread vaccination to control these outbreaks, Kennedy has characterized immunization decisions as personal choices to be made through doctor consultation.

Noah Sliwa, a Lansing father of two, said Kennedy’s policies have validated his family’s approach. He and his wife had already chosen to space out their children’s vaccinations to better monitor potential side effects and opted against the birth dose hepatitis B vaccine for both children, contrary to previous federal recommendations.

“We felt more understood,” said Sliwa. “It felt normalized.”

Michigan health officials interviewed described observing direct connections between Kennedy’s views and vaccination rate changes. Statewide 2025 data shows nearly a three-percentage-point decrease in toddlers receiving their initial MMR shot, which Kennedy frequently criticizes.

Among white toddlers statewide, the seven-shot series completion rate fell four points to 67.5% between January 2025 and January of this year. Hispanic toddlers saw a 4.6-point drop to 69.8% during the same timeframe. Federal officials established an 80% series completion target for nationwide disease prevention over ten years ago, though they have concentrated on improving specific vaccine uptake since the pandemic.

Letha Martin, who supervises immunization programs in Oakland County north of Detroit, provides training for nurses on addressing parental vaccine hesitancy. The populous, predominantly white suburban county experienced a 2.9-percentage-point decline in toddler vaccination rates from January 2025 to January 2026, according to the analysis.

Martin reported that parents frequently expressed safety concerns about childhood shots when requesting exemptions from state vaccine requirements. Now families reference Kennedy’s specific arguments, such as claims that vaccine clinical trials inadequately test for adverse effects.

“Those are very, very particular concerns,” Martin said.

Within Michigan’s Latino community, childhood vaccination series completion rates had partially rebounded after COVID-19. However, intensified Trump administration immigration enforcement prompted more families to restrict activities outside their homes, including medical appointments, due to deportation fears, according to local health officials and advocates.

Centro Multicultural La Familia, a Latino advocacy organization in Oakland County, collaborates with county officials to organize periodic vaccination clinics. Previously, up to twelve people would typically attend these immunization sessions, said Oakland County Health Officer Kate Guzmán.

As deportation activities intensified in Michigan last year, Guzmán noted that no one attended the vaccine clinic held at the county health department, which is located adjacent to the local jail and sheriff’s department.

Detroit community leader Angela Reyes, who facilitates partnerships between Latino organizations and local health departments, reflected on the broader implications: “One of the greatest public health achievements was vaccinations, and we’re going backwards.”

MADISON, Wis. — Wisconsin lawmakers have reached agreement on a $133 million initiative to address contamination from persistent chemicals known as PFAS, sending the bipartisan legislation to Governor Tony Evers on Tuesday and concluding years of political disputes between the Democratic governor and GOP legislators.

Governor Evers indicated he would sign the measures into law immediately following the Senate’s approval Tuesday afternoon. This uncommon cross-party agreement provides hope for numerous Wisconsin municipalities dealing with PFAS contamination in their water supplies.

“Beautiful,” said Campbell Town Supervisor Lee Donahue regarding the Senate’s decision. Citizens in this community of 4,300 people have relied on bottled water since 2021 when state health authorities alerted them that over 500 wells contained contamination. “This has been a long time coming. This is definitely a day for celebration.”

PFAS chemicals — per- and polyfluoroalkyl substances — are synthetic compounds that resist natural breakdown. These substances appear in numerous consumer goods, from cookware to stain-resistant fabrics, and were previously common in aviation firefighting foam. Research has connected these chemicals to health issues such as low birth weight, cancer, liver disease, and reduced vaccine effectiveness.

Towns near industrial facilities and military installations across America face PFAS contamination challenges. Federal estimates indicate nearly half of American households have detectable PFAS levels in their water supply, whether from private wells or municipal systems. However, while federal authorities have established stringent standards for utility-provided water, these regulations don’t cover approximately 40 million Americans who depend on private wells.

Multiple Wisconsin communities are battling PFAS groundwater contamination, including Marinette, Madison, Peshtigo, Wausau, Stella, and Campbell. Green Bay’s waters also show contamination.

In Stella, private wells suffered severe PFAS contamination from fertilizer containing these chemicals that was applied to agricultural land. State resources for assistance have been limited, with restricted free testing availability and only modest grant programs for well replacement.

The governor and Republican legislators have disagreed for years about the best approach to tackle this pollution. Wisconsin’s 2023-25 budget established a $125 million trust fund for PFAS remediation, but both sides couldn’t reach consensus on spending priorities.

Two years ago, Evers rejected a Republican proposal that would have allocated funds for grants to municipalities, property owners, and waste facilities for PFAS testing in treatment plants and wells. The governor argued the legislation restricted state regulators’ ability to pursue polluter accountability, and environmental organizations supported his veto.

During the political impasse, the fund has increased to $133.4 million, according to Legislative Fiscal Bureau data.

The original bill’s primary sponsors, Republican Senator Eric Wimberger and Representative Jeff Mursau, introduced two revised proposals in January following consultations with the state Department of Natural Resources, which reports to Evers.

The first measure allocates $132.2 million from the PFAS trust fund for community grants, well replacements, airports, and industrial sites, plus $1.3 million from the general fund for 10 additional Department of Natural Resources staff positions to oversee the program.

The second bill creates a liability exemption list for contamination, resembling the 2024 legislation Evers vetoed. Exemptions include individuals who spread PFAS while following permits that didn’t address PFAS; property owners whose land was contaminated under permit conditions; owners of contaminated industrial sites who didn’t cause the pollution; and fire departments that used PFAS-containing foam. However, businesses operating facilities that have used PFAS or spread industrial waste could still face liability.

The Assembly approved both bills unanimously on the final day of its two-year session in February. The Senate passed the legislation by overwhelming margins, with one bill receiving a 33-0 vote and the other passing on a voice vote with minimal debate.

“I’m incredibly proud we were able to work across the aisle to get this done — and get it done right,” Evers stated.

South Carolina health officials documented another measles infection on Tuesday, pushing the state’s total number of cases to 997, according to new data released by the state health department.

The latest figure represents an increase of one case since Friday’s report. Health authorities are cautioning that this expanding outbreak may continue for an extended period, potentially lasting several weeks or even months, as vaccination rates remain below optimal levels in affected areas.

Pharmaceutical company Pfizer announced Tuesday that a new experimental drug combination showed promising results in treating breast cancer patients, demonstrating a 40% reduction in the risk of disease progression or death.

The treatment pairs Pfizer’s investigational drug atirmociclib with fulvestrant, an established hormone therapy. Researchers conducted the mid-stage clinical trial on patients whose breast cancer had metastasized and who had undergone previous treatments.

The study compared this new drug combination against standard treatment options including fulvestrant alone or a combination of everolimus and exemestane, which represents a commonly prescribed targeted therapy approach for postmenopausal women diagnosed with the most prevalent form of breast cancer.

Trial participants included patients whose cancer had returned quickly following treatment with CDK4/6 inhibitors, a patient population that typically presents greater treatment challenges. More than 90% of study participants began taking atirmociclib within three months after discontinuing their previous cancer medication.

According to Pfizer, the experimental treatment demonstrated a tolerable safety profile, with only 6.4% of patients discontinuing the therapy due to adverse effects. The company noted that overall survival statistics, which serve as a secondary endpoint, remain preliminary and insufficient for drawing definitive conclusions at this time.

The positive trial results will support Pfizer’s plans to evaluate atirmociclib in earlier stages of breast cancer treatment, including first-line therapy and early-stage disease, where extended disease management could benefit a larger patient population.

Atirmociclib functions as an oral medication that specifically targets CDK4, a protein involved in cell cycle regulation that promotes tumor development. Pfizer has already initiated a comprehensive late-stage clinical study examining the drug’s effectiveness in patients recently diagnosed with metastatic breast cancer.

The small African kingdom of Eswatini has launched distribution of a revolutionary HIV prevention medication that requires just two injections annually, health officials announced Wednesday.

Since December, approximately 2,000 residents have received the innovative treatment called lenacapavir, making Eswatini one of only eight nations worldwide to deploy this cutting-edge prevention method.

“People have been very receptive,” stated Sindy Matse, who manages Eswatini’s National AIDS Programme. She noted that initial demand was so strong that supplies were nearly depleted.

The breakthrough medication, developed by California-based Gilead Sciences, addresses significant challenges faced by traditional daily HIV prevention pills known as PrEP. Many patients struggle with remembering daily doses or maintaining consistent access to medication supplies.

Health authorities plan to expand availability across all 206 medical facilities currently providing PrEP services throughout the kingdom, formerly known as Swaziland.

The United States, where researchers created the drug, along with seven African nations experiencing high HIV rates, have also introduced the twice-yearly injection program.

Eswatini faces one of the world’s most severe HIV challenges, with approximately 25% of residents aged 15-49 carrying the virus according to 2023 data from the U.S. Centers for Disease Control. However, the nation has made remarkable progress, reducing new infections by nearly 75% between 2010 and 2024 – dropping from 14,000 annual cases to 4,000 through improved prevention and treatment efforts.

CHICAGO, March 17 – A federal judge has temporarily blocked Health Secretary Robert F. Kennedy Jr.’s sweeping changes to childhood vaccination policies, but public health experts warn that months of controversy have already undermined confidence in vaccines.

“The genie is out of the bottle. We’re going to have to live with that,” said Michael Osterholm, director of the University of Minnesota’s Center for Infectious Disease Research and Policy.

The ruling came in response to a legal challenge filed by the American Academy of Pediatrics and other groups against Kennedy and the Health Department. The decision overturns significant portions of Kennedy’s efforts to overhaul national vaccine policy, which included cutting back on childhood immunization recommendations.

However, the victory could be short-lived if federal officials choose to challenge the court’s decision.

U.S. District Judge Brian Murphy determined that Kennedy illegally restructured his Advisory Committee on Immunization Practices after dismissing all 17 independent public health and infectious disease specialists who previously served as vaccine advisers.

Public health officials had warned that these personnel changes could undermine the nation’s immunization program and damage public confidence when the dismissals were first announced. In his Monday decision, Judge Murphy described the majority of Kennedy’s 15 personally selected panel members as “distinctly unqualified.”

Richard Hughes IV, who represented the American Academy of Pediatrics in court, recognized that harm had already occurred despite their legal win. The lawsuit was essential to “stop the continued destruction of science‑based policy for vaccines,” he said.

A representative from the U.S. Department of Health and Human Services responded: “HHS looks forward to this judge’s decision being overturned.”

KENNEDY REDUCES VACCINE RECOMMENDATIONS

Throughout the past year, Kennedy’s modifications to vaccine policy frequently bypassed the government’s established evidence-based review procedures.

During the reconstituted panel’s September session, Kennedy’s appointees decided to eliminate routine COVID vaccine recommendations, instead advising individuals to discuss vaccination decisions with their healthcare providers – an approach known as shared clinical decision-making.

In December, the panel chose to end the long-standing policy of universal hepatitis B vaccination for newborns, despite data showing this practice had decreased hepatitis B infections in children by 99%. The change was made without supporting scientific evidence.

Kennedy unilaterally reduced the federal childhood immunization schedule in January without consulting the panel or providing scientific justification. He moved four vaccines from routine recommendations to shared clinical decision-making status. As a result, the Centers for Disease Control and Prevention now broadly recommends 11 vaccines, down from the previous 17.

Health experts noted that parents have always been able to discuss vaccines with their doctors, but changing vaccines from routine recommendations to shared decision-making creates unnecessary concerns about vaccine safety, according to Osterholm.

“It creates doubt if you now have to discuss it with your doctor,” he explained.

STATES ABANDON CDC VACCINE RECOMMENDATIONS

The policy changes have prompted numerous states to reject CDC childhood vaccination guidelines.

According to a March 10 survey by the nonprofit health policy organization KFF, approximately 30 states plus the District of Columbia announced they would not follow the updated CDC recommendations for at least some childhood vaccines. Among these, 27 states said they would completely disregard CDC guidance for all childhood vaccines.

Most of these states have indicated they will instead adopt recommendations from the American Academy of Pediatrics, which has provided vaccine guidance since the 1930s, decades before the CDC’s advisory committee was established in 1964.

While the AAP previously coordinated its vaccine schedules with federal guidelines, the pediatric organization abandoned this practice last year, declaring that ACIP’s process was “no longer credible.”

Dr. Demetre Daskalakis, who previously directed the CDC’s National Center for Immunization and Respiratory Diseases before leaving the agency in August alongside three colleagues in opposition to Kennedy’s vaccine policies, expressed satisfaction that they successfully sounded the alarm.

“Now we need to repair the damage these HHS actions have caused and the disease that they have allowed to propagate,” he stated.

CONFLICTING POLICIES CONFUSE PARENTS

Medical professionals report that the shifting policies have created conflicting messages and increased uncertainty among parents, with some now questioning even standard newborn care like vitamin K administration.

Healthcare providers are fielding calls from confused parents unsure about vaccination decisions, said Alison Barkoff, a health law and policy specialist at George Washington University who supported the AAP’s legal brief.

A February KFF survey revealed that public trust in the CDC for dependable vaccine information has dropped to its lowest level since the COVID-19 pandemic began.

According to Jen Kates, a senior analyst at KFF, a court-mandated reversal cannot immediately undo months of politically charged discussions.

“It’s not like you can flip a switch and say, ‘OK, let’s go back to where we were,’” she said.

A federal court has temporarily blocked the Trump administration from moving forward with significant modifications to childhood vaccination guidelines, including proposed reductions in recommended immunizations for young people.

The preliminary injunction stops the implementation of the administration’s comprehensive revision of current vaccine protocols while legal proceedings continue.

The court action comes as health officials and advocacy groups have raised concerns about potential impacts on public health and childhood disease prevention programs.

The Food Safety and Inspection Service has announced it will seek to extend its Public Health Information System data collection program, which is set to expire at the end of November 2026.

Following federal requirements under the Paperwork Reduction Act of 1995 and guidelines from the Office of Management and Budget, the agency has formally declared its plans to continue the existing information gathering system without any modifications.

The Public Health Information System serves as a key tool for the Food Safety and Inspection Service to monitor and track food safety data across the nation. The agency’s request indicates it will maintain the current structure and processes of the information collection program.

The renewal process follows standard federal procedures for extending approved data collection systems that support public health monitoring and food safety oversight activities.

Amber Walcker unleashed a powerful cry that echoed across the Puget Sound waters, joining approximately twelve other participants in West Seattle as they released their built-up tensions into the evening air.

This marked only the beginning. Two additional group sessions followed, each building in duration and intensity, helping Walcker process the emotional weight of her recent unemployment. The stress of parenting two small children seemed to melt away as her voice mixed with the sounds of nearby waves, leaving her with a profound sense of peace.

“I had such a sense of feeling grounded. In that same moment, all your senses are heightened,” Walcker said. “From then on out, I was hooked.”

That September gathering launched Seattle’s branch of Scream Club, which has become part of a nationwide movement featuring 17 locations that have emerged within the past year across cities including Austin, Texas; Chattanooga, Tennessee; Atlanta; Detroit; and San Juan, Puerto Rico.

The original Chicago location emerged from relationship challenges experienced by its creators.

Founders Manny Hernandez and Elena Soboleva had recently begun living together following eighteen months of maintaining a long-distance relationship. During a lakefront walk along Lake Michigan, Hernandez, who works as a breathwork practitioner and men’s coach, proposed they release their relationship tensions by shouting from a pier’s edge.

After requesting permission from nearby bystanders, the entire group decided to participate, their collective voices carrying their emotions across the water.

“After we did it, some people were crying, including Elena,” Hernandez said. “That’s when we looked at each other and said, ‘This is probably something that we should start.’”

Chapter meetings vary between weekly and monthly schedules depending on location, but consistently occur in parks or waterfront areas to reduce noise complaints. Each session starts with members documenting their concerns on environmentally-friendly paper.

Participants then engage in coordinated breathing exercises and voice preparation activities, including humming techniques combined with controlled breathing patterns.

“You can really strain your throat if you just do it,” said Soboleva, a personal brand and business mentor. “So it’s gradual, breathing from your diaphragm and carefully starting off slow and warming up to louder and louder.”

The group performs three synchronized screaming rounds with breathing breaks between each session, while discarding their written concerns into the water.

“That third scream, you have to feel it in your body,” said Walcker, who established the club’s Seattle chapter. “Get down, be in a primal stance, whatever it feels like to you in that moment.”

These Scream Club methods draw from primal scream therapy concepts developed by Los Angeles psychoanalyst Arthur Janov during the 1960s. Janov theorized that early life trauma generated adult psychological issues, which could be addressed by accessing painful emotions and expressing them through screaming and tears under professional guidance.

Subsequent decades of research have not validated scream therapy as an effective mental health treatment, according to Ashwini Nadkarni, a psychiatry professor at Harvard Medical School.

However, the practice offers excellent stress reduction benefits.

Nadkarni explained that screaming stimulates brain circuits within the amygdala and hippocampus — “the oldest part of our brain” responsible for managing stress and emotions. The act also triggers the sympathetic nervous system’s fight-or-flight response. When screaming concludes, the parasympathetic system activates, instructing the body to enter rest mode.

“It’s the same cycle of regulation that happens when you exercise,” she said. “Your heart’s racing, you get short of breath, and then you relax and you feel that calm.”

Beyond physical benefits, the communal aspect of gathering with others provides additional advantages.

“The idea of people getting together to enhance community in ways that help them blow off some steam is incredible,” she said.

Hernandez noted that while publicly discussing personal motivations isn’t required, many participants stay afterward to discuss their struggles. Chicago chapter attendees have included individuals grieving recent losses, someone facing cancer for a second time, and many dealing with relationship difficulties.

Walcker observed that some participants even attend to express joy through screaming. Regardless of motivation, the Seattle group typically gathers before sunset to observe the sun setting over the water following their sessions.

“It’s kind of like putting everything to rest,” she said. “And that everyone knows that that’s the end of that, and we can all start fresh.”

A federal judge issued a temporary restraining order Monday preventing Health Secretary Robert F. Kennedy Jr. from reducing childhood vaccination guidelines, ruling that Kennedy likely broke federal procedures when he overhauled a critical vaccine advisory panel.

The court order stops Kennedy’s January directive that would have eliminated universal recommendations for children to receive vaccines against influenza, rotavirus, hepatitis A, hepatitis B, certain types of meningitis, and RSV.

Major medical organizations sounded the alarm over Kennedy’s vaccination policy changes, warning they would weaken defenses against six different diseases. The American Academy of Pediatrics and other groups modified their existing lawsuit filed in July, requesting the court intervene to prevent the reduction of the nation’s childhood immunization guidelines.

The initial legal challenge, filed in Boston federal court, targeted Kennedy’s move to stop recommending COVID-19 vaccines for most children and expectant mothers.

The lawsuit was expanded as Kennedy implemented additional measures that concerned medical associations, prompting plaintiffs to ask Judge Brian E. Murphy to address these policy shifts as well. The updated legal filing requested court review of Kennedy’s actions regarding the Advisory Committee on Immunization Practices, which provides guidance to public health authorities on vaccination recommendations for healthcare providers and patients.

Kennedy, who was a prominent vaccine opponent before assuming the nation’s highest health position, dismissed all 17 committee members last year and installed a new group that includes multiple vaccination critics.

Murphy, appointed to the federal bench by President Joe Biden, determined that Kennedy’s restructuring of ACIP likely broke federal statutes. He suspended the new appointments and all decisions made by the reconstituted committee.

Department of Health and Human Services spokesperson Andrew Nixon responded: “HHS looks forward to this judge’s decision being overturned just like his other attempts to keep the Trump administration from governing.”

The committee had planned to convene this week to review COVID-19 vaccines and other matters, but that meeting is now delayed.

“ACIP as currently constituted cannot meet,” stated Richard Hughes IV, legal counsel for the AAP. “How can a committee meet without nearly the entirety of its membership?”

Federal health authorities announced Monday that seven individuals across three states have contracted E. coli infections connected to raw milk cheddar cheese, with most victims being young children.

The Food and Drug Administration identified California company Raw Farm as the probable source of the contamination, though the agency noted that no Raw Farm products have shown positive E. coli results during testing conducted throughout the outbreak timeframe.

Health officials documented cases spanning from September 2025 through mid-February. California reported five infections, while Florida and Texas each recorded one case. Children age 3 and under accounted for more than half the victims, and two individuals required hospital treatment.

Despite FDA recommendations for a voluntary product withdrawal, Raw Farm has refused to remove its raw cheese items from store shelves.

The Centers for Disease Control and Prevention advised consumers to “consider not eating” these products.

Raw Farm owner Mark McAfee defended his decision against recalling the cheese, stating investigators haven’t established a definitive connection between his products and the illnesses.

“They have found no pathogens in any of our products,” McAfee stated during an interview. He challenged the FDA’s conclusion that the cases showed genetic similarities and criticized the timing of the outbreak announcement as too early.

According to the FDA, interviews with three infected individuals revealed all had consumed Raw Farm brand raw milk cheddar cheese. Laboratory analysis of patient samples demonstrated that the E. coli strains responsible for their infections shared close genetic relationships.

Health investigators continue gathering details from the remaining four cases. The ongoing investigation aims to pinpoint the contamination source and determine if other products may be involved in the outbreak.

NEW YORK, March 16 – The leader of Genentech, a division of pharmaceutical giant Roche, announced Monday that her company is working to develop obesity treatments that patients can both afford and tolerate without severe side effects.

Ashley Magargee, who serves as chief executive of the Genentech unit, addressed attendees at the Reuters Pharma USA 2026 conference in Philadelphia, highlighting concerns about patient retention in obesity treatment programs.

“A lot of patients are dropping off therapy for various reasons,” Magargee explained during her presentation, identifying two key areas her company plans to focus on: helping patients maintain weight loss over extended periods and developing combination treatments for individuals who don’t respond well to single medications.

Magargee emphasized the dual challenge facing the pharmaceutical industry in obesity treatment, asking: “How can you not just get these new medicines to patients, but also, how can you get an affordable portfolio of medicines to treat all the needs across the patient population now?”

The executive’s comments come as the healthcare industry continues to grapple with making effective obesity treatments accessible to a broader range of patients who need them.

Twenty years ago, Tom McGee started using stairwells for workouts as a strategy to quit smoking. The 69-year-old Chicago-area market researcher has faced an unexpected challenge: security guards who view his exercise routine with suspicion.

“I’ve gotten kicked out of about every hotel in the city,” McGee explained.

While stair climbing has gained recognition in fitness recommendations, regular practitioners report difficulties accessing stairwells due to building management restrictions in office towers.

Medical professionals strongly advocate for this form of exercise. Dr. Luis Rodriguez, a 66-year-old semi-retired pediatric pulmonologist who competes in stair-climbing competitions, emphasized the comprehensive workout benefits.

“You are working your legs. You are working your heart. You are working your lungs,” Rodriguez noted. “You can get a lot more benefit than just walking, because gravity is working against you.”

Scientific studies support these claims, showing that four minutes of stair climbing equals approximately 10 minutes of fast-paced walking or 20 minutes of leisurely walking.

Federal fitness guidelines updated in 2018 began encouraging brief activity bursts, such as consistently choosing stairs over elevators at work. These recommendations highlight how small activities throughout the day can accumulate meaningful health improvements without requiring lengthy workout sessions.

Virginia Tech exercise specialist Stella Volpe observed that many individuals “don’t realize that they don’t have to exercise all in one bout for it to be effective.”

University of Georgia public health researcher Jennifer Gay noted additional benefits, explaining that stair climbing may boost mental wellness and increase energy levels.

Medical experts advise that individuals with mobility concerns should consult physicians before beginning stair climbing routines.

The American Lung Association organizes annual “Fight for Air” fundraising events in office buildings nationwide each spring. While these events are enjoyable, organizers explain the name references the breathlessness participants experience after ascending multiple floors, similar to symptoms of respiratory conditions.

Property owners often restrict stair access due to liability concerns. Legal advisors warn landlords and building operators about potential lawsuits if individuals slip or fall on staircases. Hazardous conditions like inadequate lighting, wet steps, and damaged railings can lead to injury claims.

Many facility managers have implemented emergency-only stair policies based on such legal guidance.

A 2018 study examining hospital emergency visits found over one million annual stair-related injuries nationwide, with fractures occurring more frequently among elderly individuals. Women comprised more than 60% of those injured.

However, Gay’s research indicates minimal injury risk for people climbing upward. Descending stairs presents greater danger, and building managers “can’t make it a one-way street,” she added.

Health advocates have spent over ten years pushing for improved stair access. In 2013, ChangeLab Solutions, a California health policy organization, published guidelines encouraging property owners to unlock stairwells, arguing they present no higher liability than other shared building areas.

Gay and her research team estimate that 60% of American workers are employed in multi-floor buildings containing stairwells. However, no data exists showing what portion of these structures limit stair usage.

Stair climbing enthusiasts frequently share stories about struggling to locate accessible staircases.

Lisa Bai, a New York real estate professional, cannot access her office building’s stairs. While this should provide convenient exercise opportunities, sometimes “it’s not,” she said.

Bai and others seek alternative stepping solutions. Exercise machines like StairMasters can simulate stair climbing workouts, though tower climb participants say these devices don’t match the intensity of actual stairs.

Creative solutions become necessary when home or public stair access is limited.

Detroit suburban residents Carmen Erickson and Vivian Dawson have maintained a stair climbing partnership for roughly ten years, typically meeting three times weekly at a local park.

Travel presents additional challenges. During joint vacations, they deliberately book top-floor rooms in tall hotels to utilize stairwells. They also seek out hills and hospital parking structures.

The pair successfully negotiated after-hours building access by signing liability waivers and checking in with security personnel during each visit.

“If you connect with the right people and tell them what they’re doing and agree to the rules, it hasn’t really been a problem for us,” said Erickson, 53.

Dawson, 64, added: “You have to really want to do it.”

Pharmaceutical companies worldwide are scrambling to find new shipping routes for life-saving medications as Middle East conflicts force the closure of major cargo airports, threatening the supply of temperature-sensitive cancer treatments and other critical drugs.

The escalating tensions, which began with U.S. and Israeli military actions against Iran two weeks ago followed by retaliatory Iranian strikes across the region, have effectively shut down crucial aviation hubs and maritime passages that serve as lifelines for medical supplies reaching Gulf nations.

Although significant medication shortages haven’t materialized yet, industry leaders warn this could rapidly change if hostilities continue. Gulf countries depend heavily on imported pharmaceuticals, many of which have limited shelf lives and require precise temperature control during transport, making lengthy ground transportation impractical.

Drug company officials report they’re actively pursuing backup routes into Gulf regions and transporting medications by truck from alternative airports including those in Jeddah and Riyadh, Saudi Arabia. Additional routing options include facilities in Istanbul and Oman.

Critical aviation centers such as Dubai, Abu Dhabi and Doha have suspended operations due to Iranian military responses to earlier U.S. and Israeli strikes. These airports serve as vital cargo connections between Europe, Asia and Africa, with carriers like Emirates and Etihad, plus logistics companies including DHL, specializing in transporting medications requiring strict temperature maintenance for safety and effectiveness.

According to Wouter Dewulf, a professor at Antwerp Management School, industry statistics reveal that more than 20 percent of worldwide air freight – the primary transportation method for urgent or life-saving medications and vaccines – faces potential Middle East-related disruptions.

One industry leader warned that establishing alternative “cold-chain corridors” – temperature-regulated pathways for sensitive pharmaceuticals – requires significant time and isn’t always feasible.

A pharmaceutical company representative revealed their organization has formed specialized teams to prioritize shipments crucial for patient care, including cancer therapies, noting that some temperature-controlled cargo might miss scheduled connections without proper storage and handling arrangements.

A medical equipment company official explained their initial response involves tracking shipments currently in transit or awaiting departure, then determining which cargo requires rerouting and whether new shipping plans are necessary.

This executive, who requested anonymity when discussing internal procedures, noted that Europe-to-Asia freight normally passing through Dubai or Doha airports is being redirected through China or Singapore. Ocean transport isn’t viable due to extended travel times and Iran’s closure of the strategically important Strait of Hormuz.

“If you have an urgent surgery with a patient waiting for treatment, you have to choose the faster mode of transport,” the executive said.

Prashant Yadav, a senior fellow for global health at the Council on Foreign Relations, explained that inventories of medications with short shelf lives, temperature requirements and higher costs typically last about three months, with cancer drugs – particularly monoclonal antibodies – facing the greatest risk.

Delivery delays for cancer medications can have devastating effects on patients, potentially forcing them to begin treatment programs over again or allowing their condition to deteriorate.

Yadav confirmed the disruption is already impacting some companies, with certain clients indicating they may face supply shortages within four to six weeks without improvement.

More than 100 pharmaceutical and logistics industry representatives participated in a webinar hosted by Pharma.Aero, a life sciences logistics organization, to address the Gulf crisis and its effects on supply chains and transportation.

Some logistics companies report the industry is managing the current situation. Dorothee Becher, who oversees air logistics for healthcare at freight company Kuehne+Nagel, said carriers are operating flights to Jeddah, Riyadh and Oman while utilizing ground transportation to reach final destinations.

“I do not see any risk yet that the inventory would go dramatically down,” she said, noting that healthcare cargo receives priority handling.

However, maintaining shipment flow requires constant effort.

Doaa Fathallah, chief operating officer at biopharma logistics company Marken, confirmed that cold-chain cargo continues moving, but only through continuous rerouting as airspace restrictions change rapidly.

The rerouting results in extended transit periods and increased fuel expenses, raising transportation costs and requiring additional dry ice to maintain medication temperatures.

Industry executives emphasize that risks increase if disruptions continue, as Gulf and Asian supplies diminish.

Transportation complications could also impact products that indirectly affect drug supplies, including shortages of vial stoppers, IV bag materials and packaging components.

“It’s not always a shortage of the medicine itself,” said David Weeks, who monitors the supply chain industry for ratings agency Moody’s. “In some cases, it’s the little stopper on the vial where the dosage is extracted.”

Family members across the nation are increasingly taking on the responsibility of caring for elderly relatives as America experiences unprecedented demographic shifts toward an older population.

The weight of providing care for the country’s growing senior population is primarily resting on the shoulders of family caregivers, creating significant challenges that impact both their daily routines and psychological wellbeing.

This demographic transformation is placing unprecedented demands on those who step forward to provide assistance and support for aging family members, often requiring substantial personal sacrifices and lifestyle adjustments.

A Tampa-based supplement manufacturer has launched a nationwide recall of honey-based products after federal testing discovered they contained unlisted erectile dysfunction medications.

Pure Vitamins and Natural Supplements, LLC announced the voluntary recall on March 14, 2026, affecting three specific products: Boner Bear Honey, Red Bull Extreme, and Blue Bull Extreme.

According to FDA laboratory testing, Boner Bear Honey was found to contain both sildenafil and tadalafil, while Red Bull Extreme and Blue Bull Extreme products contained sildenafil. These are the same active ingredients found in prescription medications like Viagra and Cialis.

The presence of these undeclared pharmaceutical ingredients poses serious health risks, particularly for individuals taking nitrate medications or those with cardiovascular conditions, as dangerous interactions could occur.

Consumers who have purchased any of these products are advised to stop using them immediately and consult with their healthcare provider if they have experienced any adverse reactions.

A medical diagnostics company revealed Tuesday that it has joined forces with technology giant Nvidia to dramatically cut the time patients wait for critical cancer test results after surgery.

Droplet Biosciences announced the partnership will utilize Nvidia’s artificial intelligence technology to analyze genetic information much faster than traditional methods. The company is implementing Nvidia Parabricks, a specialized software system that uses advanced processors to rapidly examine DNA sequences.

The breakthrough allows doctors to identify remaining cancer cells within 24 hours by examining fluid from the lymphatic system collected during surgery. This represents a massive improvement over current blood-based testing methods, which typically require four to six weeks before tumor remnants can be detected.

According to Droplet’s chief scientific officer, Wendy Winckler, the AI acceleration has transformed their most complex computational processes. “By leveraging NVIDIA Parabricks’ acceleration, we’ve been able to compress some of our most computationally intensive steps from more than a day down to just a few hours,” Winckler explained.

The company reported that while the advanced computing technology costs more per hour to operate, the significantly shorter processing time actually reduces the total expense for each patient sample analyzed.

This rapid turnaround means patients can receive their test results before leaving the hospital, eliminating the need for additional appointments or extended waiting periods associated with conventional blood testing procedures.

Zhuosheng Gu, senior director of informatics and research at Droplet Biosciences, highlighted another improvement in their workflow. “We are using Parabricks to speed up our genomic analysis and shorten turnaround time from 10 days to less than five days,” Gu stated.

The startup’s initial clinical application focuses on HPV-negative head and neck cancer testing, which has received validation under Clinical Laboratory Improvement Amendments standards. Droplet Biosciences participates in NVIDIA Inception, a program designed to support AI startups, and serves as a customer of NVIDIA AI Enterprise services.

Medical experts have long encouraged people to “exercise your brain” to ward off dementia, but new research reveals that diversifying mental activities may be more effective than sticking to just one type of puzzle or game.

Rather than simply becoming proficient at daily crosswords, scientists are discovering that engaging in multiple brain-challenging pursuits creates a cognitive fitness routine that can strengthen different areas of the brain as people age.

A recent research project found connections between reduced Alzheimer’s risk and sustained intellectual engagement throughout life. Activities such as reading, writing, language acquisition, chess, puzzle-solving, and museum visits from youth through senior years showed protective benefits.

“They kind of like stretch your brain and your thinking. You’re using your different cognitive systems,” said neuropsychologist Andrea Zammit of Rush University Medical Center in Chicago, who directed the research.

According to Zammit, people who missed out on these brain-enriching pursuits earlier in life can still benefit by starting during middle age. Scientists are currently investigating various approaches to maintaining mental sharpness, including musical training, bird observation, and specialized brain exercises.

“It’s not just one activity. It’s more about finding meaningful activities that you might be passionate about,” Zammit noted, emphasizing the importance of long-term commitment over casual participation.

Maintaining physical wellness also plays a crucial role in brain protection. Medical professionals recommend cardiovascular exercise, blood pressure management, quality sleep, and staying current with vaccinations.

Dr. Ronald Petersen, an Alzheimer’s researcher at the Mayo Clinic, warns that no guaranteed formula exists to prevent dementia or typical age-related cognitive changes. However, he believes lifestyle modifications can help “slow down the arc of deterioration.”

Zammit’s research followed almost 2,000 adults between ages 53 and 100 who were initially free of dementia over an eight-year period. Participants answered questions about their educational background and mentally stimulating activities across different life stages while undergoing comprehensive neurological evaluations.

While some participants eventually developed Alzheimer’s disease, those with the most extensive lifelong learning experienced symptom onset five years later compared to those with minimal cognitive engagement, according to findings published in Neurology journal. Additionally, maintaining mental activity during midlife and beyond correlated with slower cognitive deterioration.

Zammit found the autopsy results from 948 deceased participants particularly compelling: individuals with more cognitively enriched backgrounds maintained superior memory and thinking abilities with slower decline before death, even when their brain tissue showed Alzheimer’s-related changes.

This phenomenon, known as cognitive reserve, suggests that learning builds stronger neural pathways across brain regions, creating resilience that helps the brain compensate for aging or disease-related damage temporarily.

While the Rush research demonstrates correlation rather than causation between mental stimulation and dementia risk, other investigations provide supporting evidence, including studies connecting brain health to musical instrument practice.

Additional research has explored “speed training” using computer programs that challenge users to identify images amid increasing visual distractions. The National Institutes of Health is currently funding a study examining whether extended computerized exercises targeting attention and response time provide lasting benefits.

Jessica Langbaum from the Banner Alzheimer’s Institute, who is not connected to the brain training studies, explains that processing speed impacts multitasking and driving abilities. She suggests choosing activities that promote quick thinking, such as participating in book clubs that combine individual reading with group discussion and social interaction.

Many chronic conditions that develop during middle age can elevate the likelihood of later dementia. High blood pressure, for instance, harms blood vessels, reducing cardiac function and brain circulation. Uncontrolled diabetes can trigger harmful brain inflammation.

Therefore, heart-healthy practices including regular physical activity, consuming plenty of fruits and vegetables, maintaining healthy weight, and managing diabetes, hypertension, and cholesterol levels also benefit brain function.

An additional protective measure involves getting vaccinated against shingles, which not only prevents the painful skin condition but emerging research indicates vaccinated individuals show reduced dementia risk.

A groundbreaking initiative to address racial bias in medical testing that prevented Black patients from receiving timely kidney transplants is showing positive results, according to new research.

Scientists announced Monday that more than 21,000 Black transplant candidates have received additional waiting list credits to compensate for time lost due to discriminatory testing practices, advancing their position in line for organ transplants as part of a restorative justice approach.

The problematic test employed a race-based calculation to assess kidney function levels. This flawed methodology caused Black patients’ kidney health to appear better than the actual condition, postponing critical diagnoses of organ failure and transplant referrals.

Following the elimination of race-based testing from the U.S. transplant network, medical facilities were mandated to review their transplant rosters and identify Black patients who should have qualified for kidney transplants earlier by examining historical medical data for previously biased results, then awarding appropriate time credits.

Medical researchers from Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, and Boston Medical Center examined transplant data spanning January 2022 through June 2025, evaluating transplant statistics before and after the January 2023 policy revision.

The research team found that among Black transplant candidates who received waiting time adjustments, the typical credit was 1.7 years, according to findings published in JAMA Internal Medicine. This represents significant time considering kidney transplant waits typically range from three to five years, though some regions experience much longer delays.

Following the policy implementation, Black patients experienced an immediate boost in transplant rates by 5.3 transplants per 1,000 listings before stabilizing. The overall kidney transplant rate grew throughout the research period, while transplant rates for non-Black patients showed no significant changes under the updated policy, with white patients maintaining the highest rates, researchers found.

“The results suggest that improving transplant care for Black individuals did not harm individuals of other races,” wrote Dr. L. Ebony Boulware of Wake Forest University School of Medicine, who was not part of the research team, in a related commentary advocating for similar measures to address damage from other incorrectly race-based medical assessments.

“Hopefully this policy helps move the needle toward equity,” stated Dr. Rohan Khazanchi of Brigham and Women’s Hospital and Boston Medical Center, the study’s lead researcher, during an interview.

Receiving wait-time credits did not result in instant transplants — 7,484 patients obtained new kidneys during the research timeframe.

The discriminatory kidney assessment relied on measuring how rapidly creatinine, a waste product, gets eliminated from the bloodstream. In 1999, the calculation formula was altered to modify Black patients’ results compared to other groups, drawing from limited studies involving small numbers of Black participants and an outdated incorrect theory regarding creatinine level differences.

This biased testing worsened existing inequalities that already put Black Americans at higher risk for needing kidney replacement while reducing their chances of receiving one. They face over three times the likelihood of kidney failure compared to white individuals and represent approximately 30% of kidney transplant candidates.

Khazanchi expressed surprise that fewer than one in three Black transplant candidates received waiting time adjustments.

This could stem from some patients not being diagnosed with kidney disease until organ failure occurred, a critical situation medical professionals term “crashing onto dialysis.” However, Khazanchi suggested another explanation might be that certain transplant facilities had better resources than others to search through historical medical files — laboratory results conducted years earlier and potentially at different healthcare systems across the country — to identify all eligible individuals.

Although the mandated review to modify wait times occurred in 2023, Black patients recently added to transplant lists should inquire about potential eligibility, he recommended.

Two major pharmaceutical companies will be partnering with the Trump administration’s prescription drug platform, according to a Friday report from Fox Business.

GSK and Amgen have agreed to include their medications on TrumpRX, the prescription drug platform created by President Donald Trump’s administration. The move represents a significant expansion of the government’s prescription drug initiative.

The announcement comes as the administration continues efforts to address prescription drug costs and accessibility for American consumers.

WASHINGTON — Federal environmental regulators announced Friday their intention to roll back air quality restrictions on ethylene oxide, a cancer-causing substance essential for cleaning medical devices, overturning stricter cancer risk protections established during the previous administration.

The Environmental Protection Agency expressed concerns that existing regulations “actively threaten” companies’ capacity to properly sterilize medical equipment and “jeopardize one of America’s only options for a secure domestic supply chain of essential medical equipment.”

While ethylene oxide serves an essential function in sanitizing life-saving medical instruments such as pacemakers and syringes, prolonged contact with the substance can lead to leukemia and additional cancer types in workers at medical sterilization plants and residents in surrounding areas.

EPA Administrator Lee Zeldin stated the recommended changes demonstrate the agency’s dedication to safeguarding public health while preserving a reliable domestic medical supply network.

“The Trump EPA is committed to ensuring life-saving medical devices remain available for the critical care of America’s children, elderly and all patients without unnecessary exposure to communities,” he said in a statement.

This announcement represents another action by the EPA under President Donald Trump to ease pollution regulations and reduce industry expenses. During February, the agency loosened mercury restrictions for coal-fired power plants and eliminated a scientific determination that formed the foundation for U.S. greenhouse gas regulation and climate change efforts.

A regulation completed in 2024 aimed to cut ethylene oxide releases by approximately 90% by focusing on nearly 90 commercial sterilization operations nationwide. The previous administration’s policy also mandated companies monitor airborne levels of the antimicrobial substance and verify their pollution control systems operate correctly.

The American Lung Association praised the 2024 regulation as a significant measure to shield public health from cancer risks associated with ethylene oxide releases. Individuals residing close to commercial sterilization operations face higher lifetime cancer risks, according to the organization.

Environmental justice supporters highlighted that numerous ethylene oxide facilities operate in minority neighborhoods where Black and Brown residents have faced exposure to the carcinogenic substance.

Ethylene oxide, or EtO, is a gas that sterilizes approximately half of all medical devices and helps ensure safety for certain spices and food items. The chemical cleans various items from catheters to syringes, pacemakers and plastic surgical garments. Short-term contact poses minimal risk, but long-term inhalation increases breast cancer and lymphoma chances, according to EPA findings.

Federal regulators initially designated ethylene oxide as a human carcinogen in 2016.

In 2022, the EPA outlined dangers for people living near medical sterilization plants. In Laredo, Texas, residents and activists worked to address contamination from a sterilization operation managed by Missouri-based Midwest Sterilization Corp. This facility was among 23 sterilizers nationwide that the EPA determined created risks for nearby communities.

Sterigenics, a leading sterilization company, closed a medical sterilization plant in a Chicago suburb following monitoring that detected emission increases in surrounding neighborhoods. The company later resolved multiple legal cases.

Scott Whitaker, president and CEO of the Advanced Medical Technology Association, emphasized that medical sterilizers deliver essential services and many devices cannot undergo sterilization through alternative methods.

“We appreciate the EPA’s efforts in listening to and understanding the importance of supplying safe, sterile medical technology without interruption while protecting employees and communities near sterilization facilities,” he said in an email.

WASHINGTON – Federal environmental regulators are moving to relax restrictions on a cancer-causing chemical widely used to sterilize medical equipment, citing concerns that stricter rules could disrupt the supply of critical healthcare devices.

The Environmental Protection Agency announced Friday its intention to modify regulations governing ethylene oxide, a toxic gas essential for cleaning roughly half of all medical devices manufactured in the United States annually. The agency argues that tighter restrictions implemented during the Biden presidency in 2024 could interfere with manufacturers’ sterilization processes.

According to the EPA, the revised approach would maintain compliance with existing federal law while reducing regulatory burdens on companies that sterilize products ranging from heart stents to wound care supplies. The changes would also protect medical device supply chains and reduce industry costs.

Healthcare professionals, industry representatives, and Food and Drug Administration officials had raised objections to the more restrictive 2024 regulations. Those rules mandated additional risk assessments and required companies to install new monitoring equipment, ventilation systems, and containment structures.

Under the new proposal, medical device manufacturers would have options when dealing with facilities that emit more than 10 tons of ethylene oxide annually. Companies could choose between implementing new monitoring technology or making alternative modifications to ventilation systems in sterilization areas.

The EPA defended the changes in an official statement, saying: “These changes better reflect the complexity of facilities and give them the flexibility to work to use safe and effective equipment to sterilize medical tools and devices without compromising clean air for all Americans.”

The agency estimates the regulatory adjustments would generate approximately $43 million in annual savings across the industry.

Ethylene oxide, commonly abbreviated as EtO, appears as an invisible gas that effectively sterilizes equipment but releases harmful pollutants into the atmosphere. Medical research has established connections between prolonged exposure to the chemical and various cancers, particularly affecting individuals residing near manufacturing facilities that produce or utilize the substance.

The regulatory proposal will undergo public scrutiny through a hearing scheduled within approximately two weeks. Citizens and stakeholders will have 45 days to submit comments before federal officials finalize their decision.

As this year’s influenza season begins to fade, federal health authorities report disappointing news about vaccine performance, with effectiveness rates among the poorest seen in more than ten years.

Health officials point to a new variant that became the dominant strain during early winter months, which poorly matched the available vaccine formulation, resulting in a severe early wave of flu cases nationwide.

Data released Friday by the Centers for Disease Control and Prevention shows continued decreases in medical visits for flu-related symptoms through the previous week. The count of states experiencing high influenza activity fell to 16, with many located in a corridor extending from Colorado through Virginia.

“The winter respiratory virus season is slowly coming to a close, and we’re all very grateful for that,” said Dr. William Schaffner, a Vanderbilt University vaccine expert.

According to CDC findings released this week, this season’s immunizations provided approximately 25% to 30% protection against flu severe enough to require medical attention at doctors’ offices, clinics, or hospitals for adults. Vaccinated children showed roughly 40% reduced likelihood of needing medical treatment at healthcare facilities.

Health authorities typically consider flu vaccines successful when they achieve 40% to 60% effectiveness. Based on previous CDC studies, this season recorded among the lowest protection rates witnessed over the past twenty years.

Influenza cases spiked dramatically in late December, hitting certain regions particularly hard. New York City health departments characterized it as the most severe season experienced in two decades.

While relatively modest flu vaccination coverage contributed to the problem, specialists primarily attributed the situation to the emerging flu variant responsible for most infections.

This new variant falls under the A H3N2 category of influenza virus. The specific version, known as subclade K, appeared to transmit more readily, though it didn’t necessarily produce more serious symptoms.

This season’s available vaccine targeted a different H3N2 version, and the rapid spread of the new variant likely explains the reduced vaccine effectiveness, according to Schaffner.

CDC researchers calculate at least 27 million cases, 350,000 hospital admissions, and 22,000 deaths from influenza during this season so far. Comparable figures from the previous year showed at least 40 million illnesses, 520,000 hospitalizations, but similar death totals.

At least 101 children have died this season. Among those with known vaccination records, approximately 85% had not received complete flu immunization.

While flu vaccines may not prevent all illness, they can reduce severity and prevent deaths, making vaccination still valuable, Schaffner emphasized.

CDC information indicates adult vaccination rates increased slightly this season to 46.5%, following last year’s particularly harsh season that established a record for pediatric deaths this century.

Roughly 48% of American children received flu vaccination by late last month. This matches last year’s rate but represents a decline from the 52% vaccinated at the same time in 2024, CDC data shows.

Beginning in 2010, federal authorities recommended yearly flu shots for Americans six months and older. However, in January, the Trump administration discontinued universal flu shot recommendations for all children, stating decisions should rest with parents and family physicians.

Meanwhile, preparations for next winter’s flu season have already begun. Last month, the World Health Organization issued recommendations for virus strains to target in vaccines for the 2026-27 northern hemisphere flu season. The organization specified that vaccines should address subclade K. This week, a U.S. Food and Drug Administration advisory panel supported the WHO guidance.

The University of Oregon has announced plans to provide medication abortion pills directly to students when the fall semester begins. This decision makes the institution the second university in Oregon to offer such services on campus, following Portland State University which already provides these medications to students.

The initiative reflects a growing trend among major universities across multiple states, with some institutions even installing vending machines to distribute the medications. According to current statistics, the majority of abortions performed in the United States now utilize medication rather than surgical procedures.

Federal health officials have broadened the approval for a respiratory syncytial virus vaccine to include younger adults who face higher risks from the infection, the pharmaceutical company GSK announced Friday.

The Food and Drug Administration has now authorized the company’s RSV vaccine, called Arexvy, for adults between ages 18 and 49 who have increased vulnerability to severe lower respiratory tract illness from the virus.

Previously, the vaccine had received approval only for Americans 60 and older, along with at-risk individuals between 50 and 59 years of age.

RSV represents a widespread respiratory infection that triggers seasonal illness similar to influenza and stands as a major contributor to pneumonia and fatalities among babies and elderly individuals.

According to GSK, approximately 21 million American adults under 50 possess at least one condition that elevates their risk for serious RSV complications.

The pharmaceutical company will now face competition in the younger adult market from rival vaccines, including Moderna’s mRESVIA and Pfizer’s Abrysvo products.

European health authorities also moved toward broader approval in December, when a European Medicines Agency committee endorsed Arexvy for all adults over 18, setting the stage for expanded availability across Europe.

WASHINGTON — Federal health regulators on Tuesday granted approval for a generic medication targeting an extremely rare neurological condition, while simultaneously rejecting earlier White House assertions that the treatment could benefit large numbers of autism patients.

The Food and Drug Administration authorized leucovorin for children and adults diagnosed with a genetic disorder that prevents folate — a crucial B vitamin — from reaching the brain. Agency experts estimate this exceptionally uncommon condition affects less than one person per million Americans.

This decision represents a dramatic departure from claims made during a White House press event in September, where President Donald Trump and FDA Commissioner Marty Makary announced the medication was being evaluated to help autism patients, particularly those with vitamin deficiencies affecting brain function.

“It might be 20, 40, 50% of kids with autism,” Makary stated during that September announcement.

The White House presentation came after Health Secretary Robert F. Kennedy Jr. pledged to identify autism’s underlying causes by September.

However, top FDA officials informed reporters Monday that their evaluation was refined to concentrate on the most compelling scientific evidence, which only validated the drug’s effectiveness for patients with the specific genetic mutation affecting brain folate levels.

The FDA officials also noted that one research study supporting the medication’s autism applications was withdrawn earlier this year.

Leucovorin functions as a folate derivative, which plays a vital role in healthy pregnancies and is advised for women planning conception and during pregnancy. The existing FDA authorization permits leucovorin’s use in minimizing chemotherapy side effects and treating a rare blood condition.

Individuals with the condition addressed by Tuesday’s approval suffer from movement difficulties, seizures, and other neurological complications that may mirror autism symptoms.

Nevertheless, medical professional organizations maintain significant uncertainty about whether the drug benefits autism patients.

The American Academy of Pediatrics does not endorse regular leucovorin treatment for children with autism, even those diagnosed with cerebral folate deficiency. While some clinical trials involving this patient subset “suggest potential benefit,” the organization notes these findings stem from limited research studies.

Outstanding questions regarding the medication haven’t prevented American physicians from prescribing it.

Research published in The Lancet last week revealed that leucovorin prescriptions for children between ages 5 and 17 increased 71% above typical levels during the three months following Trump’s late September announcement. Additionally, families with autistic children have encountered difficulties obtaining filled prescriptions recently.

FDA officials informed reporters the agency is permitting foreign pharmaceutical companies to import the drug to address supply shortages. GSK, the medication’s original producer, has no plans to resume manufacturing its version.

Trump administration officials initially chose to evaluate the drug after consulting with an Arizona neurologist who prescribes it for autism patients and operates an online educational platform promoting this experimental treatment approach.

The underlying theory suggests certain autism patients possess specific antibodies that prevent folate from entering brain tissue. However, the Autism Science Foundation and other organizations highlight that non-autistic family members of people with the disorder frequently carry identical antibodies, indicating they likely don’t contribute to the condition.

Although autism has no singular cause, most researchers agree scientific evidence points to genetic and environmental influences as contributing factors.

The grocery retailer Lidl US has pulled a popular chocolate candy from its stores nationwide after discovering the product contains hazelnuts that weren’t listed on the packaging.

The company announced a voluntary recall for all packages of Favorina Chocolate Ladybugs – German-Style Nougat sold in 3.52-ounce boxes with the UPC code 20304492. The recall affects every production batch of this particular candy.

According to the recall notice, customers with hazelnut allergies could face severe or potentially fatal reactions if they eat this chocolate product. The missing allergen information on the label creates a serious health hazard for people who rely on ingredient lists to avoid dangerous foods.

Shoppers who purchased this candy should not consume it and can return the product to any Lidl location for a full refund. Anyone with questions about the recall can contact Lidl customer service for more information.

Each year, thousands of Americans lose their lives while waiting for life-saving organ transplants. Now, two economists are proposing a controversial solution they believe could dramatically increase organ availability and save lives.

The researchers argue that providing financial compensation to the families of organ donors could address the severe shortage that continues to plague the nation’s healthcare system. Their economic analysis suggests that monetary incentives would encourage more families to consent to organ donation during their most difficult moments.

The proposal comes as waiting lists for organ transplants continue to grow, with patients often waiting months or years for a compatible donor. The economists believe their approach could transform the current system and provide hope for those facing life-threatening conditions.

This discussion highlights the ongoing challenge of balancing ethical considerations with practical solutions to save lives in the medical field.

Ultragenyx Pharmaceutical announced Thursday that their investigational gene therapy demonstrated promising results in a late-stage clinical trial for patients suffering from a rare inherited liver condition.

The experimental treatment, known as DTX301, showed an 18% improvement in controlling ammonia levels after 36 weeks of treatment in patients diagnosed with ornithine transcarbamylase deficiency, also called OTC deficiency, when compared to those receiving a placebo.

OTC deficiency occurs when patients lack a crucial liver enzyme responsible for eliminating ammonia from the body. Without this enzyme, dangerous levels of ammonia accumulate in the bloodstream, potentially causing mental confusion, seizures, and even coma in severe cases.

According to the pharmaceutical company, patients generally responded well to the gene therapy treatment. The most frequently reported adverse effects involved liver complications, which medical teams successfully managed using steroid medications.

Pharmaceutical manufacturer Eli Lilly has discovered a dangerous chemical contamination in unauthorized copies of its weight-loss medication, prompting the company to issue safety warnings and demand a nationwide product recall.

In a public statement released Thursday from Washington, Lilly revealed that compounded medications combining vitamin B12 with tirzepatide – the active component in both Zepbound weight-loss treatment and Mounjaro diabetes medication – contain a harmful impurity created during manufacturing.

This announcement represents Lilly’s most recent effort to combat drug compounding facilities that the pharmaceutical company claims are producing illegal versions of its medications.

The company has initiated legal action against compounding operations, wellness facilities, and various businesses selling products that allegedly contain tirzepatide.

Compounding companies have defended their operations, claiming legal protection under specific federal regulations that permit customized drug preparation when patients need medical modifications, such as vitamin additions or dosage variations unavailable in brand-name products.

Laboratory analysis conducted by Lilly on products acquired from compounding pharmacies, medical spas, and telehealth providers revealed “significant levels of an impurity that results from a chemical reaction between tirzepatide and B12,” according to the company’s official statement and research documentation provided to Reuters.

The contamination appeared in every sample examined during Lilly’s investigation, affecting all ten products tested.

“Nothing is known about its short- or long-term effects in humans, the potential impact on the drug’s interaction with the GLP-1 and GIP receptors, toxicity, immune reactions, or how it is absorbed, distributed, metabolized, and eliminated,” the company warned in its published letter.

David Hyman, Lilly’s chief medical officer, emphasized the regulatory concerns, stating: “FDA (the U.S. Food and Drug Administration) warns that compounded products can be risky for patients because they are not reviewed for safety, effectiveness, or quality. Adding a reactive substance like vitamin B12 without clinical testing or FDA review introduces additional unknown risks.”

Lilly has informed the Food and Drug Administration about these discoveries and requested immediate recall action for all products containing both substances.

Federal regulators previously sent warning notices to 30 telehealth companies in September for making false or deceptive statements about compounded weight-loss drug alternatives.

The FDA also issued threats against “illegal copycat drugs” following telehealth provider Hims & Hers Health’s February announcement that it would begin distributing a compounded version of Novo Nordisk’s Wegovy medication.

Hims subsequently abandoned its compounded pill plans and revealed this week that it will instead offer authentic Wegovy and Ozempic products through its platform.

A Washington DC community program is preparing senior volunteers to offer their time and attention to individuals seeking someone who will simply listen without charge.

The initiative, known as Friendship Bench DC, draws its inspiration from the original Friendship Bench program that began in Zimbabwe. The local version focuses on teaching mature volunteers the skills needed to provide compassionate listening services to community members who need emotional support through conversation.

The program emphasizes creating meaningful human connections by pairing trained older adults with people who are looking for someone to talk through their concerns or experiences in a supportive environment.

A comprehensive new study released Thursday reveals that approximately one-third of Americans have been forced to reduce spending on essential items like food and utilities in order to afford medical care, as healthcare expenses continue climbing alongside the general cost of living.

The extensive research, conducted by the West Health-Gallup Center between June and August 2025, surveyed nearly 20,000 adults across all 50 states and Washington D.C. The findings show that 33% of participants had to make at least one financial sacrifice in their daily spending to cover healthcare expenses.

The impact proves most severe for Americans without health insurance coverage, where 62% reported making financial compromises for medical care. Among uninsured respondents, 32% had to take out loans while 24% extended the use of current medications longer than recommended.

Even those with insurance coverage aren’t immune to these financial pressures, as nearly 30% of insured Americans have also made spending sacrifices, according to the survey results.

The situation has worsened in 2026 as most Americans with private insurance face increased premiums and higher out-of-pocket expenses, particularly affecting millions enrolled in government-subsidized Affordable Care Act plans where additional COVID-era financial assistance has ended.

Timothy Lash, president of West Health Policy Center, a nonprofit organization dedicated to healthcare and aging issues, expressed concern about the broader implications. “We’re actually finding that people are reporting higher incidences of metabolic disease or depression and anxiety. We’re not getting healthier as a society, we’re actually getting sicker, and the healthcare cost is going up on top of it,” Lash stated.

A separate study involving 5,660 American adults, conducted primarily through Gallup’s research panel from October through December of last year, examined how medical expenses are affecting major life decisions. The research found that Americans have postponed significant life events or changes over the past four years specifically because of healthcare costs, including purchasing homes or taking vacations.

The second survey, also released Thursday, found that nearly 9% of participants delayed their retirement plans due to medical expenses, while double that percentage reported putting off career changes for the same reason.

Biotechnology company Regenxbio announced Wednesday that preliminary findings from their clinical trial demonstrate ongoing enhancement of muscle function in patients receiving their investigational gene therapy for Duchenne muscular dystrophy.

The company reported that the early-to-mid stage research revealed their experimental treatment maintained a favorable safety record while continuing to show positive effects on muscle performance in study participants diagnosed with the genetic disorder.

Duchenne muscular dystrophy is a progressive muscle-wasting disease that primarily affects boys and typically leads to significant disability and shortened lifespan.

American tap water typically meets safety standards and maintains high quality, though taste and delivery can differ between locations and buildings.

This variability has driven significant growth in the water filtration industry, with products ranging from basic pitcher systems to expensive reverse osmosis units costing thousands. However, environmental specialists indicate that most American homes don’t require comprehensive water treatment systems. The key challenge lies in determining whether filtration is actually necessary for your situation.

Through the Safe Drinking Water Act, the EPA establishes health requirements for over 90 contaminants found in public water supplies, covering both chemical substances and microorganisms. Water companies use disinfectants such as chlorine to eliminate dangerous bacteria before distribution to residences. The majority of public water systems comply with these regulations, making tap water safe for most Americans.

Gregory Pierce, who directs the Human Right to Water Solutions Lab at UCLA, explained his perspective: “Unless you’re experiencing health impacts, you’ve got a notice from your water system or there’s a credible media story saying your water is unsafe, you shouldn’t feel the need to get a filter. You’re still welcome to because it might make your water taste a little bit better, but it shouldn’t be considered necessary to have a water filter in 90-plus percent of the United States.”

Understanding how to evaluate local water conditions, determining when water analysis is worthwhile, and selecting appropriate filtration that addresses specific issues without overspending are important considerations.

Begin by reviewing your water company’s yearly Consumer Confidence Report, which outlines discovered contaminants and compliance with federal requirements. These documents are usually found on municipal or utility websites, though you can also reach out to your provider for additional information. Water companies typically maintain responsibility only until water reaches private property lines, so quality can differ between buildings.

These reports may provide sufficient confidence for many consumers. However, some individuals seek additional assurance, particularly in aging structures.

Jess Goddard, who serves as chief science officer at environmental testing company SimpleLab, recommends: “You should probably test your water to identify if you have a risk that you need to treat.”

Private wells operate under different maintenance and safety requirements since they fall outside Safe Drinking Water Act regulations, making homeowners responsible for monitoring. The EPA provides resources specifically for private well owners.

Testing packages can range from several hundred dollars upward, depending on the contaminants being screened.

The testing process typically involves ordering a kit, collecting water samples according to provided instructions, and mailing them to certified laboratories. Labs examine samples for specific contaminants including PFAS chemicals, microplastics, metals, and disinfection byproducts before issuing reports.

When testing identifies serious problems, Pierce suggests contacting your water utility or state environmental agency for assistance. High contaminant levels may require solutions beyond household filtration, such as temporary bottled water use or infrastructure improvements like pipe replacement.

If issues don’t warrant such extreme measures, filtration systems may provide benefits.

Consumers should identify their filtration objectives and understand different filter capabilities. The EPA notes that many household uses like toilet flushing and laundry don’t require treatment, so cooking and drinking water are primary considerations.

Most filters receive certifications from nonprofit organizations NSF and the American National Standards Institute. Standard NSF/ANSI certifications include 42 for taste or odor issues, 53 for health-related effects, and 401 for emerging contaminants. An NSF database enables searches by product name or targeted compounds.

Sydney Evans, a science analyst who directed a water filter testing initiative at the Environmental Working Group, noted: “Not every filter is good for everything. And even if there’s a filter out there that does absolutely everything, maybe you don’t need it.”

Many families choose filters not for safety reasons, but to address taste or smell issues, “which really do impact people’s enjoyment or sense of confidence in their drinking water,” according to Goddard.

For these situations, basic carbon filters, including many standard pitcher models, can prove effective. Activated carbon removes chlorine and compounds created when chlorine interacts with natural organic materials in water.

These compounds are normal in treated water, explained Samantha Bear, a senior research analyst at SimpleLab. Even when levels remain below federal thresholds, she and her team filter their tap water not because it’s dangerous, but to minimize long-term exposure.

Even residents in areas without significant PFAS contamination may worry about these substances. PFAS stands for perfluoroalkyl and polyfluoroalkyl substances. The EPA states that filters can lower PFAS concentrations but encourages people to contact local water providers first when concerns arise.

Lead represents another contaminant that often exceeds filtration system capabilities. Since the EPA maintains that no lead level is safe, people may choose filters even where alternative water sources or pipe replacement aren’t recommended.

Pitcher systems, refrigerator filters, and faucet-mounted units process water at point of use locations where you drink or cook. Under-sink systems and reverse osmosis units also treat water at taps but may need professional installation.

Whole-house systems process water at entry points, filtering water before distribution throughout homes. These systems typically cost more and often require professional installation. They’re generally used for issues affecting all household water like hardness, elevated iron levels, or certain volatile compounds, rather than contaminants originating in plumbing.

Besides filtration systems, some homes use water softeners to reduce mineral presence that can accumulate and harm plumbing, though these systems don’t eliminate most other contaminants. Distillation systems, which boil water and condense steam to remove minerals and some contaminants, are less common in residential settings.

Most households don’t require whole-house or distillation systems unless addressing specific, documented problems, experts indicated.

Proper maintenance and filter replacement also matters, since cartridges can lose effectiveness or permit bacterial growth without following manufacturer replacement schedules.

“Otherwise they may do more harm than good,” warned Pierce, the UCLA researcher.

AMSTERDAM — Megan Worthy fondly remembers her childhood days performing with a choir in Canberra, Australia.

Today, at 58 years old, Worthy faces a devastating battle as an uncommon type of early-onset dementia gradually deteriorates her eyesight and other cognitive abilities. Yet when she joins her daughter Bronte in a special musical program at Amsterdam’s renowned Concertgebouw concert hall, those cherished memories of her youth come flooding back.

“It’s pretty brutal,” Worthy said of her rare neurological condition. “I’m starting to lose everything, you know, and this is really rewarding and seeing all these people, yeah, it did make me have a lot of memories.”

Worthy participates in what organizers call a “singing circle” — a therapeutic program led by opera performer Maartje de Lint at the prestigious venue. The sessions welcome elderly individuals with what de Lint describes as “vulnerable brains,” including those battling various forms of dementia and Parkinson’s disease.

Dementia affects millions worldwide, causing gradual deterioration of memory, thinking abilities, language skills and other mental functions. The condition can alter personality traits, emotional regulation and even how people perceive their surroundings. While Alzheimer’s disease remains the most familiar type, numerous other forms exist with distinct symptoms and causes. Vascular dementia, for instance, develops when small strokes reduce blood circulation to brain tissue.

Participants in the Amsterdam program, who each contribute 20 euros ($23.50) per session, gather with their caregivers in a circular seating arrangement beneath 14 sparkling crystal chandeliers in the venue’s elaborate Mirror Hall.

“We always say, music is like vitamins,” said Selien Kneppers, 78, who once managed a Dutch boogie woogie and blues band and now regularly attends the singing circle.

De Lint moves dynamically throughout the center of the group, frequently kneeling beside participants and extending her hands to create personal connections. She and fellow performers from her organization travel extensively across the Netherlands and Europe conducting similar musical workshops.

According to de Lint, singing serves as a method for maintaining brain function while strengthening bonds between family members and their affected loved ones.

“So we give people perspective,” she says before one of her singing sessions in Amsterdam. “It’s like actually a training for the brain, for the body, to get more resilient and understand the perspective that you still have.”

The 60-minute sessions create profound emotional responses among participants and caregivers alike. Volunteers frequently distribute tissues as tears flow freely. During one touching moment, a man gently caressed the cheek of the woman beside him while the group performed classics including Elvis Presley’s “Love Me Tender,” Frank Sinatra’s “Fly Me to the Moon” and “Amazing Grace.”

Neurobiologist Brankele Frank, who operates independently from de Lint’s initiative, supports the idea that singing provides meaningful benefits for individuals with dementia, Alzheimer’s and other brain degenerative conditions.

Music “speaks to brain areas that haven’t really been degenerated yet,” she told The Associated Press. “So, for example, their verbal skills often are compromised, but music speaks to parts of the brain that don’t necessarily need verbal skills. And so it taps into their emotion, their sense of self, their identity.”

Researchers continue investigating music’s therapeutic potential for people suffering from dementia, brain trauma, Parkinson’s disease and stroke. Musical experiences activate numerous brain regions simultaneously, reinforcing neural pathways that control language, memory, emotions and physical movement.

Bronte Henfling, Megan’s daughter, expressed appreciation for bringing her mother to an uplifting environment that wasn’t focused on medical discussions about her posterior cortical atrophy diagnosis.

“Just hearing everyone come together and sing … it reminds us that we’re all human and there’s a humanity out there which is really pleasing and nice to be a part of,” she said.

WASHINGTON — Federal health officials are raising ethics concerns about the Food and Drug Administration’s chief drug regulator, Dr. Tracy Beth Hoeg, who is attempting to bring on board a personal associate pushing for controversial new pregnancy warnings on antidepressants, according to an Associated Press investigation.

The associate, Dr. Adam Urato, specializes in maternal-fetal medicine and has submitted a formal request asking the FDA to place a prominent boxed warning on SSRI antidepressants. His proposal claims these widely-prescribed depression medications may cause pregnancy losses and brain development issues in unborn children that could result in autism and other conditions.

Sources with knowledge of internal FDA operations tell the AP that this labeling change has become Hoeg’s primary focus. She maintains regular communication with Urato and is actively pursuing his employment at the agency, according to these individuals who requested anonymity due to the sensitive nature of the matter.

FDA personnel consider Hoeg’s personal connection to Urato a significant ethical violation that would typically require her to step away from any decisions involving his proposal. However, she continues to personally expedite the agency’s evaluation of her associate’s request, sources indicate.

Medical professionals outside the agency express skepticism about the proposal, noting it depends on questionable evidence from animal testing and limited human studies. They worry that additional FDA warnings might prompt expectant mothers to abandon necessary treatment, creating dangerous health consequences from unmanaged depression.

“A black box warning is a big red flag with both practitioners and patients,” said Dr. Jennifer Payne, a University of Virginia reproductive psychiatrist. “What’s missing in this petition is an understanding of the risks of maternal mental illness during pregnancy, not just to the woman, but to the pregnancy and ultimately the infant.”

SSRI medications encompass many of the most commonly prescribed depression treatments, including brand names like Prozac, Paxil, and Zoloft, along with their generic versions.

Federal data shows more than 15% of American women — approximately 26 million individuals — use depression medication. Current medical guidelines indicate these drugs are typically safe for pregnant women and should only be stopped following thorough discussion with healthcare providers.

During an autumn presentation to senior FDA drug administrators, Hoeg discussed the SSRI proposal as her own work. Staff members who examined her presentation materials discovered they had been prepared by Urato, according to sources who spoke with the AP. This incident was initially disclosed by Stat News.

In a Wednesday email response, Urato described Hoeg as “an excellent scientist” and confirmed their multi-year professional relationship.

“I am friendly with her, as I am with many colleagues, but we do not have a longstanding personal friendship that would in any way prevent her from reviewing the citizen petition,” Urato stated.

A representative from the Department of Health and Human Services, the FDA’s parent agency, indicated the administration would provide a direct response to Urato regarding his proposal.

This past January, Urato received an appointment to the Centers for Disease Control and Prevention’s vaccine advisory committee, which Health Secretary Robert F. Kennedy Jr. has restructured to include multiple vaccine-skeptical members.

The antidepressant matter represents another divisive issue undertaken by Hoeg, a sports medicine doctor without prior government or administrative background.

Throughout the COVID-19 crisis, Hoeg gained recognition for opposing mask requirements, vaccination mandates, and similar public health policies. She collaborated on research with medical dissidents who later joined the current administration, including FDA Commissioner Marty Makary and the agency’s vaccine director, Dr. Vinay Prasad. All three have become prominent advocates for Kennedy’s agenda.

Prior to the pandemic, Hoeg had authored only a small number of medical publications, including research on health challenges facing ultramarathon athletes.

The Danish-American physician and distance runner played a key role in the Republican administration’s recent elimination of several childhood vaccine recommendations. This represents a policy shift she has long advocated to align American practices more closely with Denmark’s approach.

Similar to many vaccine critics, including Kennedy, Hoeg has expressed doubts about antidepressants, challenging both their safety profile and therapeutic value. Last July, she organized an FDA expert panel on SSRIs featuring Urato and nine additional medication critics.

“Never before in human history have we chemically altered developing babies like this, especially the developing fetal brain, and this is happening without any real public warning,” Urato stated during that gathering.

During a subsequent podcast appearance, Hoeg repeated many of Urato’s arguments.

“I think women should be informed about the potential risks so that they have time to come off SSRIs if they want to when they’re trying to get pregnant,” Hoeg explained to the Mom Wars podcast hosts.

FDA leadership generally refrains from public commentary on pending reviews to avoid suggesting decisions are based on personal viewpoints rather than scientific evidence.

Nevertheless, Hoeg has taken direct control of the SSRI evaluation, instructing FDA personnel that their proposed nine-month review schedule required shortening, according to informed sources.

Processing a citizen petition requires comprehensive examination of scientific documentation, legal considerations, and multiple procedural steps to ensure the agency’s ultimate determination can withstand court challenges.

“Apart from it serving FDA’s public health mission, there’s always going to be some concern about legal risk if the agency doesn’t take sufficient time to consider all the relevant data and arguments,” explained Patti Zettler, a former FDA legal counsel now teaching at Ohio State University’s law school.

Hoeg assumed leadership of the FDA’s drug division in December, taking charge during extraordinary organizational turmoil involving layoffs, voluntary departures, and management transitions. She represents the sixth individual to oversee the 5,000-employee center within the past year.

Staff members received no direct communication from Hoeg until a town hall meeting last month, where she expressed safety concerns about both SSRIs and injectable RSV medications for children — a drug category the FDA is reassessing at her direction. RSV is a respiratory infection that hospitalizes thousands of American children annually.

Antidepressant safety has faced scrutiny for decades, resulting in multiple label modifications including a black box warning about suicide risk in young people.

Current labeling for pregnant women identifies several confirmed safety concerns, including increased bleeding risks following delivery.

Physicians treating women with depression report they routinely discuss these risks with patients, weighing potential medication dangers against the serious consequences of depression relapse: self-injury, substance abuse, and other behaviors that harm both mothers and developing babies.

Researchers who have examined Urato’s SSRI petition indicate many studies claiming links to conditions like autism fail to account for other significant health variables. For instance, women with depression experience higher rates of smoking, diabetes, and family mental health histories that can all elevate developmental disorder risks.

“So how do we say that these outcomes are a result of the SSRI when all of these other factors are at play?” questioned Dr. Amritha Bhat, a University of Washington perinatal psychiatrist.

Bhat and fellow researchers endorse additional SSRI research and recognize potential medication drawbacks.

“But in the meantime we need to provide options to people that are struggling with these symptoms during pregnancy,” she emphasized. “We cannot just ask them to white knuckle their way through it.”

Federal health investigators known as “disease detectives” will deploy to South Carolina next week to assist with the nation’s most significant measles outbreak in more than three decades, state health officials announced Wednesday.

Three specialized officers from the Centers for Disease Control and Prevention’s Epidemic Intelligence Service will focus on examining information gathered during the prolonged health crisis, according to Dr. Linda Bell, who serves as South Carolina’s state epidemiologist.

The deployment comes after a dozen public health specialists from the nonprofit CDC Foundation arrived in South Carolina last week to provide additional support. The CDC Foundation operates as an independent organization established by Congress to assist the CDC’s mission.

Dr. Bell explained that while CDC Foundation personnel have been handling “day to day work that supports those disease containment efforts,” the incoming federal officers will concentrate on processing the extensive amount of data accumulated over nearly 22 weeks since the outbreak began.

State health department officials noted last week that the CDC’s typical practice of providing short-term deployments lasting only a few weeks does not adequately address the ongoing operational needs required for sustained outbreak response efforts.

The Food and Drug Administration will see a leadership change next month as its chief operations officer prepares to retire from federal service.

Barclay Butler, who serves as the FDA’s deputy commissioner for operations and chief operating officer, will be stepping away from his position after holding these roles for approximately one year, according to an internal agency communication obtained by Reuters.

FDA Commissioner Marty Makary informed staff members that Melanie Keller, currently serving as Butler’s deputy, will assume his responsibilities beginning April 6. Keller brings three decades of professional experience working within the Department of Health and Human Services to her new role.

During the transition period, Butler will remain with the agency in a consulting capacity, holding the designation of COO Emeritus, before his official departure in the coming months.

A biotechnology company saw its stock value plummet more than 25% in after-hours trading Wednesday following news that federal health officials have temporarily suspended its clinical trial for a rare muscle disorder treatment.

The Food and Drug Administration imposed a partial clinical hold on PepGen’s mid-stage testing of PGN-EDODM1, an experimental therapy designed to treat myotonic dystrophy type 1. This inherited condition gradually weakens muscles and causes them to contract involuntarily, creating difficulties with movement and everyday tasks.

According to PepGen, the FDA’s decision stems from questions about laboratory and animal research data the company had previously provided to regulators.

However, the agency has not identified any safety issues related to patient information collected during earlier human testing phases.

Company officials stated they are collaborating with the FDA to resolve the regulatory concerns and plan to provide additional data, including recently revealed results from prior studies.

Despite the American suspension, PepGen has received authorization to launch the trial in South Korea, Australia, and New Zealand.

The study is already underway in the United Kingdom and Canada, where patients are receiving the 10 mg/kg dosage after an independent safety monitoring committee recommended proceeding with higher dose levels.

The clinical hold affected no American participants since patient enrollment had not yet begun in the United States.

PepGen reported having $148.5 million in cash and investments at the end of December 2025, providing sufficient funding for company operations through mid-2027.

Diabetes medications including Ozempic and Mounjaro may offer unexpected benefits in combating addiction, according to groundbreaking research published March 4 involving U.S. military veterans.

Scientists discovered that GLP-1 medications used to treat diabetes demonstrated protective effects against multiple addictive substances, ranging from alcohol and nicotine to cocaine and opioids. This broad impact surprised researchers who typically see treatments targeting specific substances.

“That breadth was quite a surprise,” stated Dr. Ziyad Al-Aly from the VA Saint Louis Health Care System in Missouri, the study’s lead researcher published in The BMJ. “In addiction medicine, there’s not a single drug that works across all these substances.”

Researchers analyzed Veterans Affairs medical records, examining patients with type 2 diabetes who received either GLP-1 medications (including Eli Lilly’s Trulicity and Mounjaro, plus Novo Nordisk’s Victoza and Ozempic) or alternative diabetes drugs called SGLT-2 inhibitors (such as Jardiance and Farxiga). Most participants used standard diabetes doses rather than higher obesity-treatment formulations.

Among 124,001 veterans without prior substance abuse history taking GLP-1 drugs, researchers found 14% reduced likelihood of developing addiction disorders over three years compared to 400,816 similar patients using SGLT-2 medications.

The protective effects varied by substance: alcohol use disorders decreased by 18%, cannabis problems by 14%, cocaine use by 20%, nicotine addiction by 26%, and opioid abuse by 25%.

For 81,617 veterans already struggling with addiction, GLP-1 medications produced even more dramatic results. Emergency room visits related to substance abuse dropped 31% over three years, hospital stays decreased 26%, addiction-related deaths fell 50%, overdoses declined 39%, and suicidal thoughts or attempts reduced by 25%.

Traditional addiction treatment follows substance-specific approaches, Al-Aly explained. Doctors typically prescribe “the antidote for substance A, such as a nicotine patch for tobacco, or naltrexone for alcohol,” he said.

“But here, you have this drug that is working across all addictive substances,” Al-Aly continued. “That’s telling us that there is likely a common biologic pathway that is driving all of these addictions that is indeed druggable or treatable by GLP-1.”

The medications likely target brain receptors located in the mesolimbic system, which controls motivation and reward responses. Al-Aly believes GLP-1 drugs work to “put the lid on cravings” by reducing brain signals that drive people toward excessive consumption of food or drugs.

Important questions remain unanswered, including whether benefits continue after years of treatment or if the brain eventually adapts and reduces the medications’ effectiveness.

“We’re very interested in fleshing this out and trying to understand this concept a little bit more,” Al-Aly noted.

The Veterans Affairs system plans to conduct a comprehensive clinical trial testing semaglutide (the active ingredient in Ozempic and Wegovy) specifically for veterans battling alcohol addiction.

Fares Qeadan from Loyola University in Chicago, writing in an accompanying editorial, advised against waiting for a single “magic bullet” solution.

“These results suggest that when GLP-1 receptor agonists are clinically indicated for cardiometabolic reasons, potential benefits for substance related outcomes may be an added consideration in shared decision making,” Qeadan wrote.

Popular diabetes medications that have transformed obesity treatment could offer new hope in battling substance abuse disorders, according to groundbreaking research involving more than 600,000 patients.

A comprehensive study released Wednesday in a medical journal examined electronic health records from U.S. Veterans Affairs patients diagnosed with diabetes. Researchers discovered that individuals receiving treatments like Ozempic and Mounjaro showed significantly lower rates of developing dependencies on alcohol, nicotine, cocaine, opioids and other substances compared to patients using alternative diabetes medications.

Among patients already struggling with addiction, these GLP-1 medications correlated with reduced hospitalization rates, fewer overdoses and lower death rates, the research revealed.

While the findings suggest these weight-loss drugs could address the fundamental brain mechanisms behind cravings affecting over 48 million Americans with substance abuse problems, the study stops short of proving causation.

“They’re actually working against the root cause of all these different addictions,” explained Dr. Ziyad Al-Aly, who led the research and serves as chief researcher at the VA St. Louis Health Care System.

Earlier research had indicated that GLP-1 medications, scientifically known as glucagon-like peptide-1 receptor agonists, might combat addiction by influencing brain reward systems. However, those investigations were typically smaller in scope and focused on single substances.

This expanded analysis, among the most comprehensive conducted to date, saw Al-Aly and his research team examine electronic medical records spanning three years from more than 600,000 Veterans Affairs diabetes patients. They contrasted outcomes between patients prescribed GLP-1 drugs and those receiving alternative blood sugar-lowering treatments.

Researchers organized participants into seven separate studies examining addiction development risks across various substances including alcohol, cannabis, cocaine, nicotine and opioids. An additional study evaluated specific health risks among individuals with pre-existing addictions using different medication types.

The investigation revealed that patients beginning GLP-1 treatment faced reduced addiction development risks across multiple substances. When compared to alternative medications, GLP-1 users showed decreased addiction risks of 18% for alcohol, 14% for cannabis, 20% for both cocaine and nicotine, and 25% for opioids.

For patients already battling substance abuse disorders, initiating GLP-1 treatment correlated with 31% fewer emergency room visits, 26% fewer hospitalizations, 25% reduced suicidal ideation or attempts, 39% fewer overdoses, and 50% lower mortality rates.

The study calculated that GLP-1 drug usage likely prevented approximately seven substance abuse cases and 12 serious harm incidents per 1,000 users across the three-year period, Al-Aly reported.

The research has notable limitations: it occurred within the VA healthcare system, serving a demographic that’s predominantly older, white and male, though Al-Aly noted consistent results among more than 35,000 female participants. The data also exclusively covers diabetes patients rather than the broader population.

Researchers couldn’t control for certain variables like economic status or personal lifestyle decisions that might influence outcomes. The analysis compared GLP-1 effects against other medications rather than no treatment at all.

As an observational investigation, the study demonstrates correlation between GLP-1 usage and reduced substance abuse risks and consequences, rather than proving the medications directly caused these improvements.

Dr. Lorenzo Leggio, a National Institute on Drug Abuse clinical director not involved in the research, called the discoveries remarkable.

“Even though we don’t fully understand the mechanism, somehow the GLP-1 system is tackling addiction biology and the foundational system that underlies all these disorders,” Leggio stated.

Clinical trials for diabetes and weight management have demonstrated that GLP-1 drugs influence gut and brain hormones controlling appetite and satiety, reducing what researchers call “food noise” or persistent food thoughts. Similarly, this study suggests the medications might diminish “alcohol or drug noise,” according to Leggio.

Dr. Anna Lembke, a Stanford University addiction medicine expert, expressed enthusiasm about mounting evidence that GLP-1s could prevent substance abuse disorders.

“We haven’t really had a new tool in our toolbox from a pharmacotherapy perspective to treat addiction in a long time,” Lembke observed, noting that some addiction specialists already prescribe GLP-1s off-label when conventional treatments prove ineffective.

However, she warned that GLP-1 medications don’t produce uniform results across all users and carry risks requiring careful consideration against potential advantages.

Al-Aly emphasized that these findings alone don’t warrant prescribing GLP-1 drugs for preventing or treating substance abuse disorders. Such evidence would require randomized controlled clinical trials directly comparing drug usage against placebo treatments. Several such studies are currently underway, Leggio confirmed.

The ultimate objective involves discovering innovative approaches to treating addictions, which represent major contributors to illness and death globally.

“The consequence in terms of chronic disease of these addictive drugs is actually gigantic in our society,” Leggio concluded.

WASHINGTON – Federal health officials announced Saturday that a key autism advisory committee has called off its planned March gathering without offering specifics about the postponement.

The Interagency Autism Coordinating Committee, which provides guidance to the health secretary regarding federal autism research funding and helps coordinate government autism initiatives, had been set to convene on March 19.

Andrew Nixon, a spokesperson for the Department of Health and Human Services, confirmed the cancellation but declined to elaborate. “The IACC will not meet later this month,” Nixon stated. “Further information will be shared as available.”

Health Secretary Robert F. Kennedy Jr. restructured the committee in January. Kennedy has a history of promoting anti-vaccine positions and has claimed that vaccines are linked to autism development.

Over one-third of the newly appointed committee members have advocated for the scientifically disproven connection between vaccines and autism spectrum disorders. Several new appointees have expressed intentions to direct federal funding toward exploring autism causes and related medical conditions that often occur alongside autism.

In response to the Kennedy-led changes, twelve autism advocates, researchers, and previous committee participants established the Independent Autism Coordination Committee last week. This alternative group plans to develop its own research strategy as an alternative to the government-appointed panel.

Imagine the workplace culture of the 1960s, where employees regularly consumed multiple cocktails during business lunches. Although such extreme drinking practices have largely disappeared, many professional environments still revolve around alcohol consumption through happy hours, company celebrations, and client entertainment at upscale establishments.

For individuals recovering from alcohol dependency, discussing their sobriety with supervisors and coworkers can feel overwhelming. Many worry about potential judgment or career limitations in industries where social drinking remains deeply embedded in professional networking.

Recovery specialists and professionals who maintain sobriety while advancing their careers emphasize that these concerns are understandable but shouldn’t prevent necessary conversations or actions that support successful recovery.

“If you’re sober and in recovery, nothing’s worth risking putting your sobriety at risk,” said Lisa Smith, a former lawyer who struggled with drug and alcohol addiction as she worked at a prestigious law firm in New York.

Smith emphasizes the importance of establishing workplace boundaries without over-explaining personal decisions.

“We say in recovery a lot that ‘No’ is a complete sentence,” Smith said.

The workplace atmosphere has evolved significantly since Smith began her career. Today’s younger professionals have embraced mocktails and alcohol-free alternatives, helping to normalize abstinence while bringing greater awareness of mental health and addiction issues to their workplaces.

Smith discovered that declining alcoholic drinks generated far less attention from colleagues than she had anticipated. She also noticed more non-drinking coworkers than she had previously recognized, whether due to religious beliefs or personal preferences.

Those who pressured her to drink were typically heavy drinkers themselves who “were looking for a comrade to drink with, to sort of make them feel better about their own drinking,” she said.

During her early recovery period, Smith avoided events she knew would be challenging or departed early, but she made sure to follow up with people she wanted to connect with over coffee the next day.

Smith currently operates her own consulting business, where she shares her journey with organizations and legal practices, helping them develop more supportive environments for employees in recovery.

“We hear from younger lawyers who understand that it is not healthy and don’t like the way they feel on alcohol, just don’t choose to drink for any reason,” she said.

The entertainment sector also promotes widespread drinking culture, according to Ermanno DiFebo, a Los Angeles production designer who battled alcohol addiction for years before achieving sobriety.

DiFebo described how alcohol was promoted with the message that “if you are good, you can handle it. If you cannot handle it, you are weak,” DiFebo said. “The treatment facilities are for people that are weak.”

Initially, he created various explanations for avoiding alcohol, such as claiming medical appointments or early morning commitments. In comfortable settings, he would simply explain, “I partied too much and now I’m not partying anymore.”

DiFebo now suggests viewing alcohol addiction similarly to food allergies – just as someone allergic to gluten would avoid it completely.

“Alcohol makes you sick and manifests itself in compulsion to continue beyond reasoning,” he said.

Creating recovery-supportive workplace cultures also benefits employers, according to Heidi Wallace, vice president of recovery services at the Betty Ford Center in Rancho Mirage, California.

“Individuals in that recovery process that are working a program, they’re actually the most productive workforce,” Wallace said. “They’ve done so much work to get to this place, and their program actually has been sitting in a space of gratitude and a place of being of service.”

Research indicates that people actively participating in recovery programs maintain better attendance and volunteer more readily for additional responsibilities, Wallace noted.

Companies can support this by providing spaces for virtual recovery meetings during work hours or hosting on-site meetings, Wallace suggested.

DiFebo remembered participating in recovery meetings on movie sets at Warner Brothers and Universal Studios.

“I realized that there were a lot of people in recovery around all the drinkers. I just didn’t see them before,” he said.

Smith works to demonstrate that companies can organize enjoyable team-building activities without centering them around alcohol.

“There was always this assumption people made that when planning events that alcohol equals fun, right?” Smith said.

Hiking excursions and wellness activities have gained popularity alongside expanded non-alcoholic beverage selections. Even wine-tasting events can accommodate non-alcoholic alternatives, Smith noted.

Simple changes like ensuring mocktails are readily available on serving trays rather than requiring separate bar orders can make events more inclusive.

“It shouldn’t be incumbent upon the person who chooses not to drink on any given night to make themselves feel comfortable in that setting,” Smith said.

THIKA, Kenya — Mary Mwangi once believed a cancer diagnosis meant certain death. She never imagined that learning to knit during her recovery would transform the lives of countless breast cancer survivors across Kenya.

Today, Mwangi crafts knitted breast prostheses for women who have undergone mastectomies but cannot access the reconstructive procedures commonly available in wealthier nations.

These budget-friendly alternatives provide hope in a country where breast cancer tops the list of cancers affecting women. Kenya sees approximately 6,000 new breast cancer cases each year, while 40% of its citizens struggle with poverty.

Mwangi’s journey started in 2017 with simple hats and scarves before she encountered another woman creating knitted breast forms.

Operating from her shared tailoring space in Thika, near Nairobi, Mwangi teaches her craft to fellow survivors through a group she calls the New Dawn Cancer Warriors. While some members earn income from their work, others find emotional healing through the creative process.

“Knitting takes you through a process of healing. Once you are not thinking about your disease, you are positive and that positive mind helps you, because healing starts from your mind,” she said.

High school science teacher Nancy Waithera credits meeting Mwangi before her operation with easing her recovery. She purchased a prosthesis and began envisioning her post-surgery life.

Her cancer diagnosis made “everything turned dark,” especially following her husband’s recent death, which deepened her despair.

However, connecting with Mwangi renewed her optimism, and she eagerly awaited her surgical site’s healing so she could wear her knitted prosthesis.

Describing her first day wearing it to church, she shared: “I felt like Nancy had come back. My ego was restored. My dignity was restored.”

Cancer treatment costs create enormous challenges in developing nations like Kenya. Government health officials report that over half of breast cancer patients receive their diagnosis only after reaching advanced disease stages, prompting efforts to improve early screening programs.

At $10 per prosthesis, Mwangi’s creations cost one-sixth the price of Kenya’s silicone alternatives. Her team produces and sells these items to organizations that distribute them to survivors who cannot afford to purchase them directly. Over the past three years, they have completed more than 600 pieces.

The yarn-based prostheses contain pillow-type fiber filling that women describe as comfortable against their skin.

Housewife and mother Hannah Mugo expressed gratitude for upgrading from stuffing her bra with clothing, which created an uneven appearance, to wearing a fiber-filled knitted prosthesis that restored her self-assurance.

“I used to stay indoors because I didn’t want people to label me as the ‘woman with one breast’,” Mugo said. After meeting Mwangi, she learned the knitting technique for personal use and commercial purposes.

Medical professionals emphasize that hobbies and peer support networks are essential for cancer patient recovery. Fellow survivor and knitter Eglah Wambui, who works alongside Mwangi, remembered a woman from her treatment period who took her own life due to depression, according to medical staff.

“Knitting is therapeutic and helps take away my thoughts,” said the mother of two.

Dr. Daniel Ojuka, a surgeon who has observed donated prostheses at Kenyatta National Hospital’s cancer center, believes that post-surgical planning and community support make recovery “significantly easier.”

Ojuka explained that mastectomy represents the most affordable treatment choice for Kenyan breast cancer patients, while breast reconstruction surgery remains financially impossible for most. The national health insurance program does not cover reconstructive procedures.

Despite surgeons preparing patients for post-operative chest changes, the emotional impact remains profound, he noted. He has witnessed patients crying upon awakening from surgery.

Mwangi no longer views cancer as a fatal diagnosis. She remains committed to teaching more women the prosthesis-making technique while maintaining their hope.

“There is life after cancer, and cancer is not a death sentence, because I’m a living testimony,” she said.

Officials in South Africa are taking steps to bring manufacturing of a groundbreaking HIV prevention medication to their own shores, working with global health organizations to identify capable local pharmaceutical companies.

The South African government has partnered with Unitaid and the United States Pharmacopoeia to find domestic manufacturers who can safely and affordably produce lenacapavir, Gilead Sciences’ twice-yearly injection that many experts believe could be a game-changer in ending the decades-long HIV pandemic.

Last year, the American pharmaceutical giant Gilead awarded six manufacturing licenses to generic drug producers in India, Egypt and Pakistan, allowing them to supply the medication to 120 developing nations, including South Africa. However, critics pointed out that no South African companies were selected for these agreements.

A seventh license for a South African manufacturer could dramatically improve access to the drug in a region where it’s desperately needed. The medication has the potential to significantly reduce new HIV infections and help end the pandemic that has persisted for 44 years.

Gilead has expressed willingness to consider additional manufacturing partnerships in Sub-Saharan Africa. “Gilead will review the proposals and assess whether required quality standards can be met before any voluntary license is granted,” the company stated in an email response.

The African continent continues to bear the heaviest burden of HIV infections worldwide. South Africa leads all nations with 8 million people living with HIV – approximately one in every five adults. The country already has pharmaceutical companies like Aspen Pharmacare that manufacture HIV treatments and sterile injectable medications.

Paul Mashatile, who chairs the South African National AIDS Council and serves as deputy president, emphasized that domestic production would benefit the entire African region.

Kenyan President William Ruto, who leads African Union efforts on local health commodity manufacturing, stressed the importance of regional self-reliance. “Africa can no longer rely on medicines produced elsewhere for diseases that affect us most,” Ruto said.

Historically, developing countries have waited years to access HIV medications that were readily available in wealthier nations. While lenacapavir is currently available in some African countries through programs supported by The Global Fund to Fight AIDS, Tuberculosis and Malaria and the U.S. government, demand is expected to exceed supply until generic manufacturers begin production.

The existing licensing agreements have also faced criticism for excluding middle-income nations like Brazil. A South African manufacturer could potentially help expand access to these countries as well, according to Unitaid officials.

Robert Matiru, Unitaid’s program director, described the potential South African partnership as a chance to broaden access further, though he emphasized that securing a license for a South African company remains the primary objective.

Expectant mothers significantly reduced their use of Tylenol following President Donald Trump’s public warning connecting the pain medication to autism, according to new research published in the medical journal Lancet.

The study examined emergency room prescription data from September when Trump advised pregnant women to stay away from Tylenol, which contains acetaminophen and is manufactured by Kenvue. Administration health officials supported Trump’s statement by referencing studies suggesting prenatal acetaminophen exposure may contribute to neurodevelopmental conditions.

Research led by Harvard professor Dr. Jeremy Faust showed the decline in Tylenol prescribing gradually returned to normal levels after several weeks, likely due to counterarguments from medical organizations challenging the President’s position.

The same investigation revealed a significant surge in leucovorin prescriptions, a folinic acid compound that Trump promoted as an autism treatment for children during his September 22 press conference.

Federal drug authorities indicated they would authorize the medication following an FDA evaluation of patient information.

The research team analyzed Tylenol prescription rates for pregnant patients visiting emergency departments during the three months preceding and following Trump’s September announcement.

Prescription rates declined by 10% overall, while orders specifically for pregnant women between ages 15-44 decreased by 16% during the initial phase of the three-month observation period. The most dramatic weekly reduction of 20% occurred in the study’s third week.

“This means that thousands of women did not have their pain or fever treated in ERs, likely because they were needlessly afraid,” said study author Jeremy Faust, an emergency physician at Brigham and Women’s Hospital in Boston.

“We think that’s unfortunate because, among the options for pain control and fever reduction, Tylenol is the safest option,” said Faust.

The analysis found no meaningful statistical changes in prescription patterns among non-pregnant women.

During the three-month period following the Presidential advisory, researchers examined electronic medical records covering approximately 90,000 emergency department visits by pregnant women, roughly 853,000 emergency visits by non-pregnant women, and 8.6 million outpatient appointments involving children.

The investigation discovered that outpatient leucovorin prescriptions for children ages 5-17 increased by 71% during the same timeframe. Initial prescriptions jumped 93% at the study’s beginning, with the largest spike occurring in week two when prescription rates more than doubled.

Although prescriptions decreased from their highest point, they remained significantly elevated by the study’s conclusion.

“In a time in which public trust in health, medicine, and science is under attack, it’s regrettable that so many families will have been misled into thinking that this medication could somehow miraculously change the lives of children with autism,” Faust added.

When contacted about the research findings on Friday, Andrew Nixon, a spokesperson for the U.S. Department of Health and Human Services, responded by referencing his social media post defending the administration’s Tylenol messaging as part of their “commitment to telling the truth about public health.”

WASHINGTON — Dr. Vinay Prasad, the Food and Drug Administration’s controversial vaccine director, is stepping down from his position for the second time in less than twelve months, following ongoing disputes over his handling of vaccine and specialty drug approvals.

FDA Commissioner Marty Makary informed agency employees about Prasad’s departure in an email sent Friday evening, noting that he will leave his post at the end of April to resume his academic career at the University of California, San Francisco.

This latest exit comes after a series of contentious situations surrounding the FDA’s evaluation process for vaccines, gene treatments, and biotechnology medications, where pharmaceutical companies have expressed frustration with the agency’s policy reversals and demands for additional clinical studies on previously approved treatments.

Last July, Prasad was temporarily removed from his position after clashing with biotechnology industry leaders, patient advocacy organizations, and conservative supporters of President Donald Trump. However, he returned to his role within two weeks with support from Health Secretary Robert F. Kennedy Jr. and Commissioner Makary.

Since joining the FDA in May of last year, Prasad, who previously worked in academia and criticized the agency’s drug evaluation standards, has pursued what appears to be conflicting regulatory approaches. While he has collaborated with Makary on initiatives designed to streamline and accelerate the FDA’s drug approval process for pharmaceutical companies, he has simultaneously implemented additional safety warnings and research requirements for certain biotechnology products and vaccines, especially COVID-19 immunizations that have drawn criticism from Kennedy, who opposed vaccines before joining the Trump administration.

Health officials in South Carolina confirmed Friday that the state’s historic measles outbreak has reached 991 cases, marking an increase of just one case since Tuesday’s report. The slow growth suggests the nation’s most significant measles outbreak in decades may be losing momentum.

The outbreak, which started in October, has primarily affected the northwestern region of South Carolina, including areas around Greenville and Spartanburg. Current data shows 52 individuals remain under quarantine due to virus exposure, while three others are in isolation.

Vaccination efforts have intensified dramatically in response to the crisis. February saw a 70 percent jump in measles vaccinations statewide compared to the same period last year. Spartanburg County experienced an even more dramatic response, with vaccination rates climbing 139 percent last month compared to February 2025.

Federal assistance continues to pour into the state. Three specialists from the CDC’s Epidemic Intelligence Service, known as “disease detectives,” are scheduled to arrive next week to help examine outbreak data. This follows the recent deployment of twelve public health professionals funded by the CDC Foundation who are already working to help contain the spread.

Analysis of the infected population reveals concerning vaccination gaps. Of the 991 cases, 925 individuals had not received measles vaccination, while 19 were partially vaccinated. Twenty-six cases occurred in fully vaccinated people, and vaccination status remains unknown for 21 patients.

According to the most recent CDC figures from March 5, the United States has recorded 1,281 confirmed measles cases in 2026, with South Carolina’s outbreak representing a significant portion of the national total.

PARIS – French authorities have concluded that a baby’s death was not connected to recalled Nestle infant formula the child had been given, according to officials in Bordeaux on Friday.

The investigation was launched after concerns arose about cereulide, a harmful toxin capable of causing severe nausea and vomiting. This toxin was found in components supplied by a Chinese vendor to multiple baby formula manufacturers, prompting safety recalls across dozens of nations and sparking widespread parental anxiety.

“Based on the current state of the investigation, the infant’s death does not appear to be linked to the formula used for feeding,” the prosecutor said in a statement.

Laboratory testing conducted on both the powdered formula and prepared milk from Nestle that the baby had consumed in the days before death revealed no presence of cereulide, according to the official statement.

This Sunday, clocks across most of the United States will jump ahead one hour as daylight saving time begins. While losing an hour of sleep might seem like a minor inconvenience, medical experts warn the effects extend far beyond feeling groggy Monday morning.

The shift to earlier sunrises and extended evening daylight disrupts your internal body clock, potentially triggering sleep problems that can persist for weeks. Medical research has documented increases in heart attacks and strokes immediately following the March time adjustment.

However, there are strategies to minimize the transition’s impact, such as seeking morning sunlight exposure to help recalibrate your body’s natural sleep-wake cycle.

At 2 a.m. Sunday, most Americans will lose an hour as daylight saving time officially starts. The change reverses on November 1 when clocks move backward an hour.

Several areas don’t participate in the time shift, including Hawaii, most of Arizona, Puerto Rico, American Samoa, Guam, and the U.S. Virgin Islands, which maintain standard time throughout the year. Many nations worldwide also practice daylight saving time, though their start and end dates vary.

While some individuals attempt to prepare by retiring slightly earlier for several nights beforehand, the adjustment proves particularly challenging for the one-third of American adults who already fall short of the recommended seven hours of nightly rest.

Your brain contains a master timekeeper that responds to light and darkness exposure. This internal rhythm operates on approximately a 24-hour schedule, controlling when you feel sleepy versus alert. These patterns shift with age, explaining why young children who wake early often become teenagers who struggle to get up.

Sunlight exposure in the morning resets this internal clock. As evening approaches, your body increases production of melatonin, a hormone that promotes sleepiness. Extended daylight from the time change interferes with this melatonin release, throwing the entire system off balance.

Insufficient sleep connects to cardiovascular disease, mental decline, weight gain, and many other health issues. Your circadian rhythm influences more than just sleep, affecting heart rate, blood pressure, stress hormone levels, and how your body processes food.

Research examining U.S. traffic deaths shows a temporary spike in fatal accidents during the initial days after the spring time change. Morning crashes showed the highest increase, which scientists linked to sleep loss.

Cardiovascular risks also rise during this period. The American Heart Association references studies indicating more heart attacks occur on the Monday following daylight saving time’s start, with stroke rates climbing for the following two days.

Medical professionals already recognize that heart attacks, particularly severe cases, happen more frequently on Mondays and during morning hours when blood clotting increases.

Scientists haven’t determined exactly why the time change amplifies the Monday pattern, but the sudden disruption to circadian rhythms may worsen risk factors like elevated blood pressure in vulnerable individuals.

Sleep specialists recommend getting outside for morning sunlight during daylight saving time’s first week to help reset your internal clock. Adjusting daily activities like meal times and exercise schedules earlier can also signal your body to begin adapting.

Avoiding afternoon naps and caffeine, along with limiting evening screen time from phones and electronic devices, makes the transition to an earlier bedtime less difficult.

Annual discussions about eliminating time changes continue. President Donald Trump has pledged to end daylight saving time during his second term. Congressional legislation called the Sunshine Protection Act, which would make daylight saving time permanent, has repeatedly failed to advance despite bipartisan support.

Medical organizations favor a different approach. Both the American Medical Association and American Academy of Sleep Medicine support ending time changes but recommend adopting standard time year-round, arguing it better matches natural sunlight patterns and human biological needs for consistent sleep.

DANBURY, Conn. (AP) — Emergency calls at the Danbury Fire Department used to trigger immediate, high-volume alarms and tones that would startle firefighters before they rushed out to potentially high-stress situations.

Captain Kevin Lunnie described the previous system as “overwhelming.” He observed significant spikes in his heart rate when those alerts sounded, which poses serious concerns in a field where cardiac issues represent the primary cause of line-of-duty fatalities.

However, the city has adopted a more gentle method. Their new system, which became operational in September, features alarms that begin quietly and slowly build in volume, accompanied by a computerized voice that calmly delivers essential information about the emergency response needed.

“It’s much easier on your nervous system,” Lunnie stated.

This southwestern Connecticut city of approximately 87,000 residents has implemented the updated alert technology across its five fire stations, becoming part of thousands of departments globally working to decrease stress levels and enhance response efficiency.

During a recent weekday demonstration at Danbury’s primary fire station, an incoming call triggered the alert with one gentle tone. “Truck 1,” announced the automated female voice. “Respond to sick person,” it continued, providing the patient’s location.

Throughout the station, soft red lighting pulsed while screens showed the emergency type and address. A countdown timer started at two minutes, with crews aiming to depart before reaching zero.

The approach proves both more peaceful and clearer compared to the previous method, which started with maximum-volume single tones followed by chaotic longer ones that shifted between high and low frequencies. Emergency dispatchers would announce calls through station speakers, which firefighters described as filled with static and difficult to comprehend.

“Most people found it very jarring,” Lunnie commented about the old system, which would shock firefighters awake at any hour.

The updated equipment connects directly to the computer-aided dispatch system. When dispatchers receive emergency calls and enter initial details, it can notify stations and units more rapidly than department personnel, while simultaneously transmitting call information to firefighters’ mobile devices and smartwatches.

According to Danbury Assistant Fire Chief William Lounsbury, this results in faster response times.

Danbury utilized approximately $500,000 from 2021 American Rescue Plan Act funds to purchase the new Phoenix G2 system, manufactured by US Digital Designs, a Honeywell subsidiary. Honeywell reports that nearly 6,000 firehouses across the United States use this same system.

Various other companies produce comparable alerting technologies installed in numerous stations throughout the country.

Supporters of the gentler method reference a decade-old research study showing that alert systems using immediately loud sounds raised firefighter heart rates by a median of seven beats per minute, versus five beats per minute with systems that gradually increased volume.

While the difference appeared relatively minor, researchers determined it was statistically meaningful.

“When the alarm was used in a ramp-up fashion — so a gradual buildup on the alarm — the heart rate was lower to the alarm, so it put less stress on their body,” explained Dr. Jay MacNeal, associate emergency medical services director for Wisconsin’s Beloit Fire Department and one of the study’s co-authors.

More than 40 Beloit firefighters participated in the research, which appeared in the Journal of Occupational and Environmental Hygiene in 2016 by investigators from Mercyhealth’s Emergency Medicine Department in Janesville, Wisconsin, and Yale University in Connecticut.

The National Fire Protection Association reports that among 51 on-duty firefighter deaths in the United States during 2024, 20 resulted from sudden cardiac death, making it the top cause of these fatalities.

In the previous year, the NFPA established new standards for fire station alerts requiring alarms and tones that begin at lower volumes, plus calm, computerized voices, recognizing the importance of stress reduction.

The International Association of Fire Fighters, representing more than 360,000 firefighters and paramedics across the United States and Canada, endorses progressive-volume alert systems. However, the organization seeks specific standards governing their design.

Sean DeCrane, the IAFF’s assistant to the general president for health and safety, noted that research on optimal methods for alerting firefighters to emergency calls remains insufficient, and each currently available system differs.

“We would like to see an industry standard that really starts to define the decibel levels, the intervals, the integration of turning on the lights, what that progression should be, and we believe the standard should be based on research,” DeCrane stated.

Chinese health authorities have granted approval for Pfizer’s weight loss injection Xianweiying, allowing the pharmaceutical giant to market the drug for long-term obesity treatment in adults across the country. The U.S. company announced the regulatory clearance through its WeChat social media account on Friday.

The newly approved medication joins a growing roster of GLP-1 receptor agonist treatments available in China’s expanding weight management sector. Competing products from companies including Novo Nordisk, Eli Lilly, and Innovent Biologics are already being sold in the Chinese market.

Sciwind Biosciences, the Hangzhou-based company that granted Pfizer licensing rights for mainland China in February, celebrated the development on their corporate website, stating: “This marks a breakthrough in field of weight management.”

Market data from investment firm Jefferies reveals strong sales performance for existing weight loss drugs on major Chinese e-commerce platforms. Novo’s Wegovy generated 260 million yuan ($38 million) in sales through Alibaba’s Tmall marketplace and JD.com during 2025, while Innovent’s competing product Xinermei achieved even higher revenue of 416 million yuan ($61 million).

Pfizer secured commercialization rights for Xianweiying, scientifically known as ecnoglutide, through its February licensing agreement with Sciwind. The partnership represents what Sciwind previously described as “an important first step to advance Pfizer’s global strategy in the metabolic field in China.”

Beyond weight management, Chinese regulators have also authorized ecnoglutide as a treatment option for patients with Type II diabetes.

Pfizer representatives have not yet provided details regarding pricing strategies or specific launch timing for the Chinese market.

Pharmaceutical giant Roche announced Thursday that its experimental weight loss medication achieved remarkable results in a recent clinical trial, with participants shedding nearly 11% of their body weight.

The drug, known as petrelintide, was tested on 493 patients over a 42-week period. Results showed participants experienced weight reduction of up to 10.7%, significantly surpassing the minimal 1.7% weight loss observed in those receiving placebo treatments.

The Swiss pharmaceutical company obtained rights to develop petrelintide through a partnership agreement with Zealand Pharma, a Danish biotechnology firm, established in the previous year. This licensing arrangement provides Roche with joint development authority over the amylin-based weight management treatment.

New research reveals that former President Donald Trump’s unfounded statements linking Tylenol to autism significantly changed how doctors prescribed medications nationwide last year.

During a White House briefing, Trump advised expectant mothers to avoid Tylenol, claiming without scientific backing that the common pain reliever causes autism. He simultaneously promoted leucovorin, an older generic medication, as an autism remedy.

Following those remarks, a study published Thursday in The Lancet shows dramatic shifts in prescribing practices occurred over nearly three months. Emergency department orders for Tylenol among pregnant women ages 15-44 fell 10% below expected levels. Meanwhile, leucovorin prescriptions for children between 5-17 years old jumped 71% higher than anticipated from late September through early December.

Medical organizations had immediately condemned the president’s statements, emphasizing that Tylenol remains safe during pregnancy and that leucovorin should not be widely prescribed for autism treatment.

“It just shows that in our country right now, health care has been politicized in a way that political messages are driving and impacting care — and not always for good,” said Dr. Susan Sirota, a pediatrician in Highland Park, Illinois, who wasn’t involved with the research.

The researchers analyzed prescription data changes against projected trends to determine what would have happened without the White House announcement. They found no comparable shifts in similar medications, indicating the changes directly resulted from Trump’s briefing.

Study co-author Dr. Michael Barnett from Brown University School of Public Health noted how unusual it was for a political leader’s unconventional press conference to influence both patient choices and medical prescribing habits.

In previous administrations, “there are lots of layers of approval and expert consensus” before officials make big announcements about medical topics, said Barnett.

The study had some limitations, including that it didn’t track all Tylenol usage since most people purchase the over-the-counter medication outside hospital settings.

Expectant mothers typically use Tylenol for pain relief or fever reduction. The Society for Maternal-Fetal Medicine warns that untreated fevers during pregnancy, especially in early stages, can increase risks for miscarriage, premature delivery and other complications. While some research has suggested possible links between prenatal Tylenol use and autism, many studies have found no such connection.

Leucovorin, derived from folic acid, is primarily used to counteract toxic effects from certain cancer treatments and address a rare blood condition. The American Academy of Pediatrics has noted studies examining its use for cerebral folate deficiency and certain autistic children.

However, the pediatrics organization does not recommend routine leucovorin treatment for autistic children. While early, limited studies have explored its potential benefits “in carefully selected cases,” the evidence remains insufficient. Additionally, the European Journal of Pediatrics retracted a study on leucovorin as autism treatment in late January.

After the federal announcement, Dr. Sirota said families in her practice inquired about obtaining leucovorin for their autistic children. She provided education about the limited evidence and potential side effects, which can include irritability, nausea, vomiting and skin conditions like dermatitis, and chose not to prescribe it.

Sirota expressed frustration with dealing with consequences from such government statements on autism.

“It feels like a pattern with our government, right? They keep building on these houses of cards that just fall down,” she said. “This politicizing of medicine just in general, and moving away from science, has been so challenging.”

CVS Health announced Thursday its collaboration with Google Cloud, a division of Alphabet, to develop an artificial intelligence-driven healthcare platform that will integrate information from multiple sources to assist customers with real-time health management.

The new system, called Health100, will serve as a comprehensive healthcare engagement platform available to all customers, no matter which pharmacy or insurance company they currently use. CVS plans to debut Health100 in 2026, with additional information expected to be shared at Google’s yearly health conference, The Check Up, later this month.

According to Tony Ambrozie, CVS’s chief digital, technology and information officer, who spoke during a media briefing, the platform will incorporate autonomous AI technology that requires little human oversight to function as a round-the-clock personal healthcare companion for users.

“It will connect benefit managers, pharmacies, providers, and digital health systems into a single consumer-centric platform,” Ambrozie explained.

The system promises to deliver quicker healthcare options while helping users find ways to minimize their personal medical expenses. Users will interact with the mobile application through AI-powered visual and voice features.

Google Cloud will provide the technological foundation for Health100 using its business-grade platform and artificial intelligence tools, including Gemini models, Cloud Healthcare API, and BigQuery systems.

Patient information security will be maintained through Google Cloud’s infrastructure and protected data storage systems, which comply with federal privacy regulations and work alongside CVS Health’s existing security and privacy measures.

This partnership follows Google Cloud’s previous collaboration with Humana, where they created a system to provide personalized responses to members’ healthcare benefit inquiries.

The rapidly evolving Middle East crisis presents a complex challenge for parents trying to help their children understand events they encounter through social media, adult conversations, or direct experience. Mental health professionals warn that even indirect exposure to warfare can significantly impact children’s thoughts, emotions, and behavior patterns.

Child development specialists strongly advocate for open communication about these difficult topics.

“Adults often believe that avoiding discussion of challenging subjects makes them disappear, but children’s reality works differently,” explained Rebecca Smith, who leads global child protection efforts at Save the Children, an international humanitarian organization. “When we sidestep or ignore conflict discussions, children can feel isolated, abandoned, and frightened. Having transparent, honest dialogue with young people becomes crucial for helping them understand current events.”

Mental health professionals offer specific recommendations for approaching these sensitive conversations with children.

Specialists suggest beginning by discovering what children already understand about situations in Ukraine, Gaza, Iran, Israel, Sudan, and other affected regions before addressing emotions like fear, sadness, anger, or worry.

Many children remain unaware that tensions have intensified between the United States and Israel versus Iran and its allied groups. Meanwhile, other young people may possess more knowledge than parents suspect while hiding their emotional responses. Children currently in or visiting Middle Eastern conflict zones have witnessed missile strikes illuminating the night sky and may personally know victims or displaced families.

“Children now watching missiles streak across their skies face a completely new and frightening reality,” Smith noted. “These events shatter a child and family’s fundamental sense of security. Previously stable and safe environments suddenly become unpredictable.”

Helping children navigate their emotions requires trusted adults to prioritize their own mental health first, according to specialists. The National Child Traumatic Stress Network advises that adults sharing their own emotions with children creates opportunities to communicate personal values and beliefs about treating others with respect. The crucial element involves avoiding assumptions about children’s thoughts or feelings.

When children resist conversation or need more time, specialists recommend patience while reassuring them of continued support and availability.

“We must honor a child’s right to decline communication, their choice to remain silent or withhold information. They experience their own emotions and mental states that they may prefer to keep private,” stated child psychologist Nataliia Sosnovenko, speaking in Ukrainian. Sosnovenko collaborates with Voices of Children, a Ukrainian organization providing psychological assistance and recording children’s wartime experiences during the ongoing conflict with Russia.

Children who choose to share their observations, emotions, or questions deserve validation of their feelings and honest, age-appropriate responses about current events, experts emphasize.

The American Psychological Association suggests providing children with fundamental, developmentally suitable information about warfare and conflict while addressing disturbing images, headlines, or conversations they’ve encountered without unnecessary anxiety-provoking details. However, parents understand their children’s needs better than anyone, specialists acknowledge.

Families with relatives in conflict regions may require additional time discussing loved ones’ safety and managing uncertainty’s challenges. Families living within these areas should establish separation contingency plans. Save the Children experts recommend keeping plans straightforward and practicing them calmly.

Young children can grasp the concept of countries fighting, but those living elsewhere may struggle distinguishing between screen images and nearby events. For American children, Iranian conflicts may appear closer than reality when frequently viewing television or social media coverage, requiring extra safety reassurance.

Older children typically comprehend warfare and its aftermath, leading to increased concern and questioning, notes the American Psychological Association. Adults might consider emphasizing controllable factors and empowering children through humanitarian support, staying informed, and combating misinformation.

UNICEF, the United Nations children’s humanitarian agency, acknowledges that having incomplete answers remains acceptable.

In Lebanon, families have taken shelter in a brick school facility since Saturday. Nora Ingdal, Save the Children’s Lebanon Country Director, reports children asking numerous questions about conflict origins and normalcy’s return.

“One daughter clung to her mother, looking up and asking, ‘Mom, why are they fighting? Why are they attacking us?’ The mother looked at me without answers. Then she asked, ‘When are we going home?’ Again, the mom looked at me,” Ingdal recounted. “I told her, ‘It’s acceptable to admit uncertainty, you cannot promise anything, but I’m here supporting you.’”

While international organizations believe children should understand global events, experts maintain adults must protect youngsters and minimize unnecessary exposure.

Parents should monitor children’s news consumption levels. Younger children require less exposure, according to the National Child Traumatic Stress Network.

Some organizations recommend completely eliminating news or restricting adult conversations about distressing events within children’s hearing range. Others suggest using these moments to teach children about journalism’s importance, locating accurate information, and identifying false or misleading content.

Save the Children encourages caregivers to demonstrate responsible digital habits, discourage sharing harmful or graphic material, and remind children to consider twice before distributing potentially inaccurate or emotionally disturbing content.

Caregivers supporting children in conflict zones must remember that some young people have never experienced peacetime and cannot disconnect from surrounding events, Sosnovenko emphasized. Professional assistance may enhance conversations and education in these situations.

“War has changed the types of people seeking our services,” she explained. “As psychological awareness improves among the population, people recognize therapy’s importance. Currently, most people and children need psychological assistance.”

Fresh research from the Pew Research Center reveals alarming statistics about teenage social media habits, showing that roughly 70% of young people between the ages of 13 and 17 are active on TikTok. Even more concerning, approximately 20% of American teenagers report using the platform continuously throughout their day.

Child safety experts are sounding the alarm about these usage patterns, raising serious concerns about TikTok’s content moderation practices. These advocates claim the platform fails to adequately prevent content that inappropriately sexualizes young users and potentially exposes them to predators and trafficking risks.

The growing concerns have prompted multiple state governments to launch formal investigations into TikTok’s practices and the potential dangers the platform may pose to minors.

A federal advisory group responsible for determining which preventive health services insurance companies must provide at no cost has delayed its March gathering, marking the third meeting in a row to be called off.

The U.S. Preventive Services Task Force, consisting of 16 medical experts who typically convene three times annually, has not assembled since March of last year. Their November session was scrapped due to a federal government shutdown, while the July meeting was suddenly called off by the Department of Health and Human Services.

“The first USPSTF meeting of this year has been postponed and will be rescheduled in the coming months,” HHS spokesman Andrew Nixon said in an email on Tuesday.

Worries have mounted over the past year that Health Secretary Robert F. Kennedy Jr. could eliminate the advisory group entirely as he works to overhaul federal oversight of vaccines, food safety, and medical treatments.

Kennedy demonstrated his willingness to make dramatic changes last June when he dismissed all 17 experts from the CDC’s Advisory Committee on Immunization Practices, a vaccine advisory board, and replaced them with just seven personally selected members, including individuals known for questioning vaccine safety.

For four decades, the USPSTF has determined which medical screenings and treatments—ranging from regular breast cancer checks to HIV prevention medications—must be offered without charge under most insurance policies.

While the task force operates as an independent volunteer organization, it depends on administrative support from the Agency for Healthcare Research and Quality within HHS.

Task force members serve four-year appointments that are staggered to ensure continuity, with some positions rotating annually. Two new members started their terms in January 2025.

A Supreme Court decision in June 2025 regarding insurance coverage for HIV prevention treatments confirmed that the Health Secretary holds authority over this preventive care advisory group.

Conservative critics have accused the USPSTF of having a liberal bias in its recommendations.

In early July, 104 healthcare organizations—including the American Medical Association and American Academy of Pediatrics—sent a joint letter to Congressional health committees asking lawmakers “to protect the integrity” of the task force.